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Abstract 
Melanoma differentiation associated gene-7 (mda-7) was discovered in the Fisher laboratory by 
subtraction hybridization of temporally spaced subtracted cDNA libraries prepared from 
terminally differentiated human melanoma cells treated with human fibroblast interferon (IFN-β) 
and the protein kinase C activator mezerein (MEZ), an approach called ‘differentiation induction 
subtraction hybridization’ (DISH). mda-7 is located in human chromosome 1q32–33 and based 
on sequence homology, chromosomal localization, and its functional properties, the mda-7 gene 
is now classified as a member of the IL-10 family of cytokines and named IL-24. The mda-7/IL-
24 cDNA encodes a protein of 206-amino acids with a predicted size of  ~24-kDa, which 
contains an interleukin (IL)-10 signature motif at amino acids 101–121 
(SDAESCYLVHTLLEFYLKTVF) shared by other members of the IL-10 family of cytokines. 
Sequence analysis revealed the presence of a 49-amino acid signal peptide suggesting that the 
molecule could be cleaved and secreted. Expression of MDA-7/IL-24 protein was detected in 
cells of the immune system (mainly by expression in tissues associated with the immune system, 
such as spleen, thymus and PBMC) and normal human melanocytes. Of interest, a progressive 
loss of MDA-7/IL-24 expression during melanoma progression suggests an inverse relationship 
between MDA-7/IL-24 expression and the evolution of melanocytes to various stages of 
melanoma. mda-7/IL-24 induces growth suppression in human melanoma and other cancer cells, 
without affecting normal cells. Subsequent studies provided consistent evidence that ectopic 
expression of	  mda-7/IL-24 employing a replication incompetent adenovirus (Ad.mda-7) resulted 
in apoptosis induction and cell death in a wide variety of solid tumors including melanoma, 
malignant glioma, carcinomas of the breast, kidney, cervix, colorectum	  , liver, lung, ovary	  	  and 
prostate sparing normal cellular counterparts, i.e., such as normal melanocytes, astrocytes, 
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fibroblasts, and mesothelial and epithelial cells. The	  in vitro	  antitumor activity of	  mda-7/IL-24 
readily translated into the	  in vivo	  situation in animal models containing human breast, prostate, 
lung and colorectal carcinomas and in malignant glioma xenografts. Moreover, the ability 
of	  mda-7/IL-24 to induce a potent “bystander	  cancer-specific killing effect”	  provides an 
unprecedented opportunity to use this molecule to target for destruction not only primary tumors, 
but also metastases. Based on its profound cancer-selective tropism, substantiated by	  in 
vivo	  human xenograft studies in nude mice,	  mda-7/IL-24 (administered as Ad.mda-7) was 
evaluated in a Phase I clinical trial in patients with melanomas and solid cancers. These studies 
document that	  mda-7/IL-24 is well tolerated and demonstrates evidence of significant (44%) 
clinical activity. This review focuses on the recent enhancements in our understanding of the 
mode of action of	  mda-7/IL-24 and its potential applications as a unique and promising effective 
cytokine-based gene therapy for human cancers. 
 
The first chapter explored the efficacy of a tropism-modified Ad-based cancer gene therapy 
approach for eradicating low CAR colorectal cancer cells. We show that in low CAR human 
colorectal cancer cells (RKO), a recombinant Ad.5/3 virus delivering mda-7/IL-24 (Ad.5/3-mda-
7) is more efficient than Ad.5 delivering mda-7 (Ad.5-mda-7) in expressing MDA-7/IL-24 
protein, inducing cancer-specific apoptosis and inhibiting in vivo tumor growth in a nude mouse 
xenograft model. Additionally, our in vitro and in vivo data confirms that BI-97C1 (Sabutoclax) 
profoundly sensitizes mda-7/IL-24 mediated toxicity in colorectal cancer. Thus, Ad.5/3-mda-7, 
alone and/or in combination with BI-97C1 (Sabutoclax), might represent an improved and more 
effective therapeutic approach for colorectal and other cancers. 
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In view of the essential roles of anti-apoptotic Bcl-2 family proteins in tumorigenesis and 
chemoresistance, efforts are focused on developing small molecule inhibitors of Bcl-2 family 
proteins as potential therapeutics for cancer. Unfortunately, due to the unique structure of Mcl-1 
as compared with Bcl-2 and Bcl-xL, currently employed inhibitors, such as ABT-737 or its 
clinical counterpart, ABT-263, display limited affinity for Mcl-1. Using nuclear magnetic 
resonance (NMR) binding assays and computational docking studies, we have recently identified 
a series of new Apogossypol derivatives, compound 3 (BI-79D10) and compound 11 (BI-97C1), 
with pan-Bcl-2- inhibitory potency.  BI-79D10 binds to Bcl- xL, Bcl-2, and Mcl-1 with IC50 
values of 190, 360, and 520 nmol/L, respectively. BI-97C1 (Sabutoclax) is an optically pure 
individual Apogossypol derivative that retains all the properties of BI-79D10 along with superior 
in vitro and in vivo efficacy. Because Mcl-1 is over-expressed in the majority of PCs, we 
hypothesized that suppressing Mcl-1 by treating human PC cells with BI-97C1 (Sabutoclax) 
would sensitize them to mda-7/IL-24-mediated cytotoxicity. 
 
The second chapter study highlights the noteworthy potential of a combinatorial approach 
involving mda-7/IL-24, a broad-acting anticancer gene, and BI-97C1 (Sabutoclax), which targets 
Mcl-1, to sensitize PC to mda-7/IL-24-mediated cytotoxicity, thereby enhancing therapeutic 
efficacy. Our data suggests that treatment with the combination regimen of mda-7/IL-24 and BI-
97C1 (Sabutoclax) induces autophagy that facilitates apoptosis in association with up regulation 
of NOXA, accumulation of Bim, and activation of Bax and Bak. Treatment with mda-7/IL-24 
and BI-97C1 (Sabutoclax) inhibited the growth of PC xenografts and suppressed PC 
development in an immunocompetent transgenic mouse model of PC.  
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The third chapter study explored the efficacy of a tropism-modified CRCA cancer gene therapy 
approach for eradicating low CAR prostate cancer cells. We showed that in low CAR PC3 cells 
Ad.5/3-CTV is more efficient than Ad.5-CTV in delivering transgene (mda-7/IL-24), infecting 
tumor cells, expressing MDA-7/IL-24 protein, inducing cancer-specific apoptosis, inhibiting in 
vivo tumor growth and exerting an antitumor ‘bystander’ effect in a nude mouse human prostate 
cancer xenograft and suppressed PC development in an immunocompetent transgenic mouse 
model of PC model. 
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Chapter 1 
 
 
 
Enhanced delivery of mda-7/IL-24 using a serotype chimeric adenovirus (Ad.5/3) in 
combination with the Apogossypol derivative BI-97C1 (Sabutoclax) improves therapeutic 
efficacy in low CAR colorectal cancer cells 
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Abstract 
Adenovirus (Ad)-based gene therapy represents a potentially viable strategy for treating 
colorectal cancer.  The infectivity of serotype 5 adenovirus (Ad.5), routinely used as a transgene 
delivery vector, is dependent on Coxsackie-adenovirus receptors (CAR). CAR expression is 
downregulated in many cancers thus preventing optimum therapeutic efficiency of Ad.5-based 
therapies. To overcome the low CAR problem, a serotype chimerism approach was used to 
generate a recombinant Ad (Ad.5/3) that is capable of infecting cancer cells via Ad.3 receptors in 
a CAR-independent manner. We evaluated the improved transgene delivery and efficacy of 
Ad.5/3 recombinant virus expressing melanoma differentiation associated gene-7/interleukin-24 
(mda-7/IL-24), an effective wide-spectrum cancer-selective therapeutic.  In low CAR human 
colorectal cancer cells RKO, wild-type Ad.5 virus expressing mda-7/IL-24 (Ad.5-mda-7) failed 
to infect efficiently resulting in lack of expression of MDA-7/IL-24 or induction of apoptosis. 
However, a recombinant Ad.5/3 virus expressing mda-7/IL-24 (Ad.5/3-mda-7) efficiently 
infected RKO cells resulting in higher MDA-7/IL-24 expression and inhibition of cell growth 
both in vitro and in nude mice xenograft models. Addition of the novel Bcl-2 family 
pharmacological inhibitor Apogossypol derivative BI-97C1 (Sabutoclax) significantly 
augmented the efficacy of Ad.5/3-mda-7. A combination regimen of suboptimal doses of Ad.5/3-
mda-7 and BI-97C1 profoundly enhanced cytotoxicity in RKO cells both in vitro and in vivo. 
Considering the fact that Ad.5-mda-7 has demonstrated significant objective responses in a 
Phase I clinical trial for advanced solid tumors, Ad.5/3-mda-7 alone or in combination with BI-
97C1 would be predicted to exert significantly improved therapeutic efficacy in colorectal cancer 
patients. 
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Introduction 
According to the American Cancer Society (www.cancer.gov), colorectal cancer is the third most 
common cancer and third leading cause of cancer-related deaths in the US. During 2010, 
142,570 new cases of colorectal cancer were diagnosed and it was expected to cause about 
51,370 deaths. Over 20% of patients present with metastatic (stage IV) colorectal cancer at the 
time of diagnosis, and up to 25% of this group will have isolated liver metastasis that is 
potentially resectable (1). The National Cancer Institute (www.cancer.gov) reported that the 
lifetime risk of being diagnosed with cancer of the colon or rectum is about 1 in 19 in males and 
about 1 in 20 in females in the US. While 20%-25% of colorectal cancer cases occur among 
individuals with a family history of colorectal cancer or a predisposing illness, about 75% of 
cases occur in people without these risk factors (2). In these contexts, there is need to develop 
novel, effective therapeutic approaches for treating colorectal cancer and genetic therapies 
represent promising therapeutic options for this neoplasm.  
Adenoviruses represent a new therapeutic modality that can be designed to deliver 
therapeutic genes and to specifically replicate in and kill cancer cells. Clinical studies proved that 
these viruses can safely be administered locally, regionally and systemically (3) and that these 
agents have efficacy in gastrointestinal cancer (4). Recombinant forms of the type 5 adenovirus 
(Ad.5) are the most frequently used serotype of Ad for gene therapy. However, to be able to 
infect the cells, Ad.5 requires the Coxsackie Adenovirus Receptor (CAR) (5, 6). In many tumor 
types, such as malignant glioma, ovarian, renal, bladder, prostate, colorectal cancers, and 
particularly when examined in primary tumor specimens, the expression of CAR is reduced or 
absent in tumor cells compared to surrounding non-tumor tissue (5, 7-10). Established cell lines 
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express higher levels of CAR compared to that observed in primary tumors or in patients. 
Reduced CAR expression limits the efficiency of transduction of cancer cells by Ad.5 (11, 12). 
This finding may in part explain why gene therapy approaches using Ad.5 have not been as 
robust or successful as the studies performed in vitro using established cell lines. An approach to 
circumventing the low efficiency of Ad.5 infection of tumor cells involves ‘tropism 
modification’ in which the virus capsid proteins that normally associate with CAR are modified, 
permitting CAR-independent infectivity of tumor cells. The infective type 3 Ad sequence within 
the Ad type 5 virus knob (Ad.5/3 recombinant virus) allows viral infectivity regardless of the 
CAR expression status of tumor cells thereby permitting efficient viral infectivity of low and 
high CAR expressing tumor cells (13, 14).  
Melanoma differentiation associated gene-7/interleukin-24 (mda-7/IL-24) was cloned in 
our laboratory by subtraction hybridization technique by inducing human melanoma cells to 
terminal differentiation upon treatment with fibroblast interferon and mezerein (15, 16). This 
novel tumor suppressor cytokine is a member of the interleukin-10 (IL-10) gene family (17-22). 
Ectopic expression of mda-7/IL-24, using Ad.5 (Ad.5-mda-7) inhibits growth and induces cell 
death in many types of cancer cell lines in vitro, without harming comparable normal human 
cells, including epithelial cells, fibroblasts, melanocytes or astrocytes (21-26). Considering its 
robust cancer-specific apoptosis-inducing ability (by inducing ER stress) and tumor growth-
suppressing properties in nude mice xenograft models, Ad.mda-7 (INGN 241) was evaluated in a 
phase I clinical trial in patients with advanced cancers. The results from this trial demonstrated 
safety and clinical efficacy (27). In addition to its direct apoptosis inducing properties, Ad.mda-7 
also shows antiangiogenic, immunostimulatory, and potent ‘‘bystander’’ antitumor activities (28, 
29). These exciting results provide direct support for using mda-7/IL-24 in developing an 
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effective gene-based therapy for cancer. Recently, we reported that in prostate and ovarian 
cancers and in malignant gliomas, mda-7/IL-24 induced an ER stress response and subsequent 
apoptosis by suppressing expression of the anti-apoptotic Bcl-2 family members thus 
demonstrating the crucial role of Bcl-2 family proteins in regulating mda-7/IL-24 function (30-
32). In this context antagonists of anti-apoptotic Bcl-2 family members might sensitize cancer 
cells to mda-7/IL-24-mediated cytotoxicity. The novel Apogossypol derivative BI-97C1 
(Sabutoclax) suppresses the pro-survival Bcl-2 family members within a clinically achievable 
dose range (33). We recently demonstrated that BI-97C1 (Sabutoclax) sensitizes prostate cancer 
cells to mda-7/IL-24-mediated toxicity (34). 
The present study explored the efficacy of a tropism-modified Ad-based cancer gene 
therapy approach for eradicating low CAR colorectal cancer cells. We show that in low CAR 
human colorectal cancer cells (RKO), a recombinant Ad.5/3 virus delivering mda-7/IL-24 
(Ad.5/3-mda-7) is more efficient than Ad.5 delivering mda-7/IL-24 (Ad.5-mda-7) in expressing 
MDA-7/IL-24 protein, inducing cancer-specific apoptosis and inhibiting in vivo tumor growth in 
a nude mouse xenograft model. Further, our in vitro and in vivo data shows BI-97C1 
(Sabutoclax) profoundly sensitizes mda-7/IL-24 mediated toxicity in colorectal cancer. Thus, 
Ad.5/3-mda-7, alone and/or in combination with BI-97C1 (Sabutoclax), might represent an 
improved and more effective therapeutic approach for colorectal and other cancers. 
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Results 
Enhanced infectivity of tropism-modified adenovirus (Ad.5/3) in RKO low CAR colorectal 
cancer cells. Experiments were designed to compare the infectivity of Ad.5/3 chimeric viruses 
(expressing luciferase or mda-7/IL-24) and Ad.5 viruses (expressing luciferase or mda-7/IL-24) 
in low and high CAR colorectal cancer cells. The Kolmogorov-Smirnov two-sample test was 
used to analyze flow cytometric histograms to determine the cumulative distribution function of 
fluorescence intensity for each sample and the difference between the cumulative distributions, 
with the D value indicating the greatest difference between the two curves. RKO cells have a 
reduced level of CAR (D value 0.03), whereas HCT116 cells have a high level of CAR (D value 
0.82) (Fig. 1A). Luciferase (Luc) activity was evaluated following infection with Ad.5/3-Luc and 
Ad.5-Luc in RKO and HCT116 cells (Fig. 1B). The infection of RKO cells with Ad.5/3-Luc 
showed a dramatic increase in luciferase activity when compared to Ad.5-Luc. On the other hand 
the relative luciferase activity of Ad.5/3-Luc compared to that of Ad.5-Luc in HCT116 was 
much lower than that observed in RKO cells. These findings indicate that transduction efficiency 
in a low CAR tumor cell background was significantly enhanced by the Ad.5/3 modification. 
Next we compared Ad.5/3 and Ad.5 expressing mda-7/IL-24 (Ad.5/3-mda-7 and Ad.5-mda-7, 
respectively) by evaluating cell viability using standard MTT assay (Fig. 1C). Ad.5-vec (empty 
Ad.5 virus) and Ad.5/3-vec (empty Ad.5/3 virus) were used as controls. In RKO cells, Ad.5/3-
mda-7 infected group had a significant reduction in cell viability whereas Ad.5-mda-7 treatment 
did not affect the cell viability. In HCT116 cells, both Ad.5-mda-7 and Ad.5/3-mda-7 inhibited 
growth with comparable efficiency (Fig. 1C).  
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Ad.5/3-mda-7 induces MDA-7 expression and enhances killing in low CAR expressing RKO 
cells. We compared the ability of Ad.5/3-mda-7 and Ad.5-mda-7 (50 or 100 pfu/cell) in 
expressing mda-7/IL-24 in RKO and HCT116 cells (Fig. 2A and B).  In RKO cells, Ad.5/3-mda-
7 generated MDA-7/IL-24 at both high and low titer whereas Ad.5-mda-7 infected groups did 
not generate MDA-7/IL-24 protein (Fig. 2A). HCT116 cancer cells generated comparable 
amounts of MDA-7/IL-24 protein upon infection with both Ad.5/3-mda-7 and Ad.5-mda-7 (Fig. 
2B). As a corollary, Ad.5/3-mda-7, but not Ad.5-mda-7, efficiently induced apoptosis in RKO 
cells, while both Ads were equally effective in inducing apoptosis in HCT116 cells as 
determined by PARP cleavage analysis (Fig. 2A and B). Similar profiles of induction of cell 
death were also observed using the trypan blue-dye exclusion test (Fig. 2C and D). Ad.5/3-mda-
7, but not Ad.5-mda-7, induced cell killing (Fig. 2C) activity in RKO cells, which correlated with 
the expression level of MDA-7/IL-24 protein. As anticipated, both Ad.5-mda-7 and Ad.5/3-mda-
7 induced cell death in HCT116 cells with comparable efficiency (Fig. 2D).  
Annexin V staining followed by flow cytometry further quantified induction of apoptosis. 
In RKO cells, infection of Ad.5/3-mda-7 at 100 pfu/cell resulted in ~70% apoptotic cells, while 
no apoptosis was observed with Ad.5-mda-7 (Fig. 3A and B). As a corollary, infection of RKO 
cells with Ad.5/3-mda-7, and not with Ad.5-mda-7, induced an ER stress response as evidenced 
by increased expression of ER stress markers BiP/GRP78 and GRP94 and downregulation of 
anti-apoptotic protein Bcl-2 (Fig. 3C) These findings confirm that Ad.5/3 chimerism maintains 
the bona fide downstream effects exerted by mda-7/IL-24. 
Ad.5/3-mda-7 exerts anti-tumor effects in RKO xenografts in nude mice. To test if the in vitro 
superiority of Ad.5/3-mda-7 over Ad.5-mda-7 in low CAR colorectal cancer cells translates into 
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the in vivo situation, we established subcutaneous xenografts of RKO cells in athymic nude mice. 
After palpable tumors of ~100 mm3 developed, the animals received 9 intratumoral injections 
over a 4-week period with 4 X 108 pfu of Ad.5-vec, Ad.5/3-vec, Ad.5-mda-7 or Ad.5/3-mda-7 
(Fig. 4). RKO cells formed large, aggressive and actively growing tumors in Ad.5-vec, Ad.5/3-
vec and Ad.5-mda-7 treated animals, while Ad.5/3-mda-7 significantly inhibited the growth of 
the RKO tumors, which was evident at weeks 4 after initiating the therapeutic treatment protocol 
(Fig. 4A and B).  The reduction in tumor growth by Ad.5/3-mda-7 was associated with increased 
expression of MDA-7/IL-24 and reduced expression of CD31, a marker for microvessels, in the 
tumor sections (Fig. 5A and B). H & E sections of the tumors also showed decreased cell density 
in Ad.5/3-mda-7-treated group compared to the other groups (Fig. 5C). These findings indicate 
that in low CAR colorectal cancer cells, Ad.5/3-mda-7 can efficiently generate MDA-7/IL-24 
protein leading to inhibition of cell proliferation and angiogenesis.  
Suboptimal doses of Ad.5/3-mda-7 and BI-97C1 (Sabutoclax) promote synergistic anti-tumor 
effect in vitro and in vivo in RKO colorectal cancer cells. We determined if suboptimal doses of 
the combination regimen of Ad.5/3-mda-7 and BI-97C1 (Sabutoclax) are capable of inhibiting 
growth of RKO cells. We first evaluated the dose and time kinetics of BI-97C1 (Sabutoclax) 
alone on RKO cells viability in vitro. A significant inhibition of cell viability was observed with 
3 µM BI-97C1 on day 3 and day 6 (Fig. 6A). A combination of suboptimal doses of BI-97C1 
(2µM) and Ad.5/3-mda-7 (50 pfu/cell) resulted in significant inhibition of viability of RKO cells 
compared to either agent alone (Fig. 6B).  The combinatorial treatment resulted in 
downregulation of prosurvival proteins Bcl-2 and Mcl-1 and induction of apoptosis as revealed 
by PARP cleavage (Fig. 6C).  
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To evaluate the effect of combinatorial treatment in vivo, nude mice bearing 
subcutaneous RKO xenografts received nine intratumoral injections of a sub-optimal dose of 1 X 
108 pfu per injection of Ad.5/3-vec or Ad.5/3-mda-7 and 12 intraperitoneal injections of 3 mg/kg 
of BI-97C1 (Sabutoclax) over a 4-week period (33, 34). The treatment was started when tumor 
size was ~100 mm3. Mice were divided into four groups; Ad.5/3-vec; Ad.5/3-mda-7; Ad.5/3-vec 
plus BI-97C1 (Sabutoclax); and Ad.5/3-mda-7 plus BI-97C1 (Sabutoclax). Tumor growth and 
weight were markedly inhibited by the combination treatment of Ad.5/3-mda-7 and BI-97C1 
(Sabutoclax) compared to the other groups at the end of the treatment period (Fig. 7). These 
findings showed that BI-97C1 (Sabutoclax) is efficient in sensitizing low CAR colorectal cancer 
cells to Ad.5/3-mda-7 treatment. BI-97C1 (Sabutoclax) was non-toxic to athymic nude mice 
(NCRnu/nu) when injected intraperitonially (up to 10 mg/kg) (34). 
 
Discussion  
HCT116 cells have high CAR and therefore are efficiently infected with Ad.5. On the other hand 
RKO cells have low CAR, which makes it relatively resistant to Ad.5 infection. Our analysis 
reveals a variable level of CAR expression in different colorectal cancer cell lines (Fig. 1A) 
indicating that for Ad delivery to be effective a strategy facilitating efficient infection of all types 
of colorectal cancer cells needs to be utilized. To overcome the low infectivity limitation of 
Ad.5, multiple groups are trying to solve the relative inefficiency of Ad.5 infection by modifying 
specific sequences within the virus capsid proteins that directly associate with CAR; i.e., 
targeting strategies are being developed to enhance viral infectivity via CAR-independent 
pathways. Several laboratories have modified the infective viral capsid “knob” to bind to surface 
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integrin proteins enhancing transformation (RGD modification) (6, 11-14). Additionally, 
insertion into the knob of multiple lysine residues (pK7) increases viral interaction with cells by 
electrostatic effects; and including portions of type 3 Ad in the viral capsid knob has also 
enhanced infectivity via CAR-independent pathways (6, 11-14). In the present study, the potent 
tumor suppressor gene mda-7/IL-24 driven by a CMV promoter has been delivered by a CAR-
independent Ad containing a chimeric fiber with the knob domain of human Ad.3 in the Ad.5 
capsid (Ad.5/3), which showed more efficient transduction of prostate, renal cancer and 
malignant glioma cells having low CAR compared with wild-type Ad.5 (35-38). This concept is 
supported by our observation that Ad.5/3-Luc showed superior luciferase transgene expression 
when compared to Ad.5-Luc in low CAR colorectal cancer cells. Similarly, Ad.5/3-Luc also 
showed enhanced infectivity in ovarian cancer cells OV-4 and SKOV3 which display moderate 
or low levels of CAR (39), as well as in renal cancer cells (40), melanoma cells (41) and prostate 
cancer (35). We presently extend these observations by demonstrating that Ad.5/3 can effectively 
deliver the potent anti-cancer therapeutic, mda-7/IL-24, in low CAR colorectal cancer cells; and 
it has similar transduction efficiency as the wild-type Ad.5 in high CAR colorectal cancer cells. 
More importantly the 5/3 modification did not interfere with the downstream killing pathway of 
mda-7/IL-24 as evidenced by induction of ER stress response markers such as BiP/GRP78 and 
GRP94; downregulation of pro-apoptotic Bcl-2 family members such as Bcl-2 and induction of 
apoptosis upon Ad.5/3-mda-7 infection of RKO cells. Therefore, Ad.5/3 might be an effective 
tool for therapeutic delivery of mda-7/IL-24 into genetically diverse colorectal tumors in vivo.  
mda-7/IL-24 induces apoptosis by downregulating the proapoptotic Bcl-2 family proteins 
(33, 42) and ectopic expression of anti-apoptotic Bcl-2 family proteins, including Mcl-1, 
interferes with the anti-tumor activity of mda-7/IL-24. Apogossypol derivatives, such as BI-97C1 
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(Sabutoclax), function as broad spectrum antagonists of anti-apoptotic Bcl-2 proteins.  These 
compounds bind to pockets formed by the BH domains of the anti-apoptotic Bcl-2 proteins and 
inhibit their ability to bind their targets (33). BI-97C1 (Sabutoclax) that also targets Mcl-1 
profoundly sensitizes prostate cancer cells to mda-7/IL-24-mediated cell toxicity (34). Similarly, 
a combination of suboptimal doses of BI-97C1 (Sabutoclax) and Ad.5/3-mda-7 profoundly 
inhibited cell viability and promoted cell death in colorectal cancer cells and also inhibited Colo 
tumor xenografts in vivo. In our studies, BI-97C1 (Sabutoclax) was found to be non-toxic even at 
high doses and although clinical trials with BI-97C1 (Sabutoclax) remain to be initiated it is 
assumed that a suboptimal dose of BI-97C1 might not be toxic and will be well tolerated in 
human subjects as well. Based on the safety profile of the individual agents, and the fact that 
mda-7/IL-24 is now in the clinic and has been shown to be safe and efficacious, this novel 
combinatorial approach may be translatable into the clinic for the treatment of advanced 
colorectal cancers in the near future. 
 
Materials and Methods  
Cell lines, culture conditions, and viability assays. Human HCT116 colorectal carcinoma cell 
lines were obtained from the American Type Culture Collection (Rockville, MD, USA). Dr. 
Jeffrey Schlom kindly provided human RKO colorectal carcinoma cell line from the National 
Center Institute (NIH, Bethesda, MD, USA). The cells were cultured in DMEM High Glucose 
(GIBCO, Carlsbad, California), supplemented with 10% FBS and 1% penicillin and 
streptomycin (Life technologies Inc. Carlsbad, California) at 37oC in a 5% CO2 95% air 
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humidified incubator. Cell viability was determined by standard 3-(4, 5-dimethylthiazol-2-yl)-2, 
5- diphenyltetrazolium bromide (MTT) assays (43). 
Generation of Ad.5.mda-7 and Ad.5/3-mda-7. Recombinant serotype 5 and serotype 5 / serotype 
3 chimeric adenoviruses expressing mda-7/IL-24 (Ad.5.mda-7 and Ad.5/3-mda-7) and control 
empty adenovirus (Ad.5.vec and Ad.5/3.vec) were generated as described (25, 35). 
Trypan blue dye exclusion and Annexin V binding assays. Cells were harvested by treatment 
with 0.05% trypsin/0.53 mM EDTA. Cells were centrifuged at 200 x g for 5 min to remove 
trypsin/EDTA. After the cell pellets were resuspended in 100 µl of PBS, 100 µl of 0.4% trypan 
blue solution were added and mixed. Trypan blue cell suspension was left at room temperature 
for 10 min before the cells were counted with a hemocytometer. Cell death was defined as the 
percentage of the stained dead cells in the whole-cell population (43). Annexin V binding assay 
was performed as previously described (42). 
Detection of Coxsackie-adenovirus receptors (CARs) on the cell surface, and preparation of 
whole-cell lysates and Western blotting analyses. Quantification of surface expression of CAR 
was performed as described previously (35, 42). Preparation of whole-cell lysates and Western 
blotting analyses were performed as described (44). The primary antibodies used were anti-
MDA-7/IL-24 (Gen Hunter Corporation ), anti-EF1α (1:1,000; mouse monoclonal; , Millipore), 
anti-Mcl-1 (1:500; mouse monoclonal; Santa Cruz), anti-BiP/GRP78  (1:500; rabbit monoclonal; 
Santa Cruz), anti-GRP94 (1:1000; rabbit monoclonal; Sigma), anti-Bcl-2 (1:1000; mouse 
monoclonal; BD Biosciences) and anti-PARP (1:1000; rabbit monoclonal; Cell Signaling).   
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Human colorectal cancer xenografts in athymic nude mice and treatment with Ad.5/3-mda-7 
and BI-97C1 (Sabutoclax). RKO cells (2 × 106) were injected s.c. in 100 µL in male athymic 
nude mice (NCRnu/nu , 4 weeks old, ~20 g body weight) (44, 45). After establishment of visible 
tumors of ~100-mm3, requiring ~8-10 days, different adenoviruses were injected intratumorally. 
The injections were given 3X the first week and then 2X a week thereafter for a total of nine 
injections. BI-97C1 (Sabutoclax) was injected intraperitoneally (i.p.) at a sub-toxic level (33) at 3 
mg/kg 3X a week throughout the study (total 12 injections). Compound was dissolved in 500 µL 
of solvent (ethanol/Cremophor EL/saline = 10:10:80). A minimum of five animals was used per 
experimental point. Tumor volume was measured with a caliper and calculated using the 
formula: π/6 × larger diameter X (smaller diameter) 2. At the end of the experiment, the animals 
were sacrificed and the tumors were harvested and preserved in formalin before embedding in 
paraffin for immunohistochemical analysis.  
Immunohistochemical staining. Immunohistochemical staining was performed as described 
(35) with anti-MDA-7/IL-24 (1:200) and monoclonal anti-CD31 (1:200) (Dako Corporation, 
Carpenteria, California, USA). 
Statistical analysis. Statistical analysis was done using the Student t-test. P < 0.05 was 
considered significant.  
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Figure Legends  
 
Figure 1. Enhanced infectivity of tropism-modified adenovirus (Ad.5/3) in RKO low CAR 
colorectal cancer cells. A) Coxsackie-adenovirus receptors (CARs) expression on the surface of 
different colorectal cancer cell lines, the K-S value of RKO is only 3%, whereas it reaches 83% 
for HCT116. B) Cells were infected with Ad.5-Luc and Ad.5/3-Luc at the indicated doses; and 
luciferase activity was measured after 48 hr. Data represent luciferase activity of Ad.5/3-Luc 
divided by that of Ad.5-Luc. C) Cells were infected with the indicated doses of virus and cell 
viability was quantified using MTT assay after 3 and 6 days of infection. 
 
Figure 2. Ad.5/3-mda-7 induces MDA-7/IL-24 expression and enhances killing in low CAR 
expressing RKO cancer cells. A and B. HCT116 and RKO cells were infected with the 
indicated doses of Ad.5-mda-7 or Ad.5/3-mda-7 and respective controls. After 48 hr of infection 
total proteins were isolated. The expression of MDA-7/IL-24, activation of PARP (as a marker 
for apoptosis) and expression of EF1α (as a loading control) were analyzed by Western blotting 
analyses in RKO (A) and HCT 116 (B) cells. C and D. Percentage of dead cells detected by 
Trypan blue dye exclusion staining for RKO (C) and HCT 116 (D) cells. Results are mean ± 
S.D. (n=3).  
 
Figure 3. Ad.5/3-mda-7 induces killing, apoptosis and ER stress in RKO low CAR 
colorectal cancer cells. 
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RKO Cells were treated with the indicated Ad for two days. A) Histogram of different groups 
assayed by flow cytometry following Annexin V-FITC/PI staining. B) Graph showing 
percentage of Annexin V- positive cells. Results are the mean ± S.D. (n=3).  C) Changes in 
GRP94, BiP/GRP78, Bcl-2, MDA-7/IL-24 and EF1α were evaluated by Western blotting 
analysis. 
 
Figure 4. Anti-tumor effect of Ad.5-mda-7 and Ad.5/3-mda-7 in RKO xenografts in nude 
mice. Subcutaneous tumor xenografts from RKO cells were established in athymic nude mice; 
tumors were injected with the indicated Ads over a 4-week period (total of nine injections). A) 
Measurements of RKO xenograft tumor volumes; points, average (with a minimum of five mice 
in each group); bars, ± S.D. B) A representative photomicrographs of tumor and wights at the 
end of the study; bars, ± S.D.  
 
Figure 5. Ad.5/3-mda-7 shows enhanced MDA-7/IL-24 production and inhibition of 
proliferation and angiogenesis in RKO low CAR colorectal cancer cells. Subcutaneous tumor 
xenografts from RKO cells were established in athymic nude mice; the tumors were injected 
with the indicated Ads over a 4-week period (total of nine injections). At the end of the 
experiment the tumors were harvested and formalin-fixed, paraffin-embedded, sectioned and 
were subjected to further analysis A) Immunohistochemical analysis for MDA-7/IL-24 
expression. B) Immunohistochemical analysis for CD31 expression. C) Monitoring of H&E 
stained sections for cellular density.   
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Figure 6. Suboptimal doses of tropism-modified adenoviruses (Ad.5/3) and BI-97C1 
(Sabutoclax) synergize resulting in decreased viability of RKO low CAR colorectal cancer 
cells. A) RKO cells were treated with the indicated concentrations of BI-97C1 (Sabutoclax). 
After 3 and 6 days, cell viability was evaluated by MTT assays. Bars, ± S.D. (n = 3). B) RKO 
cells were infected with 50 pfu/cell of Ad.5/3-vec or Ad.5/3-mda-7 for 24 hr after which cells 
were treated with indicated concentrations BI-79C1 (Sabutoclax) and MTT assay was performed 
at 3 and 6 days. C) Analysis of expression of the indicated proteins by Western blotting.  
 
Figure 7. The combination of Ad.5/3-mda-7 and BI-97C1 (Sabutoclax) additively inhibit 
the growth of low-CAR colorectal cancer xenografts in vivo. Subcutaneous tumor xenografts 
from RKO cells were established in athymic nude mice; the tumors were injected with the 
indicated Ads with and without BI-97C1 (Sabutoclax) over a 4-week period (total of nine 
injections each). A) Measurements of RKO xenograft tumor volumes; points, average (five mice 
in each group); bars, ± S.D. B) Left: Measurement of tumor weight at the end of the study; 
Right: Images of the tumors at the end of the study; columns, mean; bars, ± S.D. 
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An Apogossypol derivative BI-97C1 (Sabutoclax) targeting Mcl-1 
sensitizes prostate cancer cells to mda-7/IL-24-mediated toxicity 
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Abstract 
Limited options are available for treating patients with advanced prostate cancer (PC). Melanoma 
differentiation-associated gene-7/interleukin-24 (mda-7/IL-24), an IL-10 family cytokine, exhibits 
pleiotropic anticancer activities without adversely affecting normal cells. We previously 
demonstrated that suppression of the pro-survival Bcl-2 family member, myeloid cell leukemia-1 
(Mcl-1), is required for mda-7/IL-24-mediated apoptosis of prostate carcinomas. Here we 
demonstrate that pharmacological inhibition of Mcl-1 expression with the novel Apogossypol 
derivative BI-97C1, also called Sabutoclax, is sufficient to sensitize prostate tumors to mda-7/IL-24-
induced apoptosis, whereas ABT-737, which lacks efficacy in inhibiting Mcl-1 does not sensitize 
mda-7/IL-24-mediated cytotoxicity. A combination regimen of tropism-modified adenovirus 
delivered mda-7/IL-24 (Ad.5/3-mda-7) and BI-97C1 enhances cytotoxicity in human PC cells 
including those resistant to mda-7/IL-24 or BI-97C1 alone. The combination regimen causes 
autophagy that facilitates NOXA- and Bim-induced, and Bak/Bax-mediated mitochondrial 
apoptosis. Treatment with Ad.5/3-mda-7 and BI-97C1 significantly inhibits the growth of human PC 
xenografts in nude mice and spontaneously induced PC in Hi-myc transgenic mice. Tumor growth 
inhibition correlated with increased TUNEL staining and decreased Ki67 expression in both PC 
xenografts and prostates of Hi-myc mice. These findings demonstrate that pharmacological 
inhibition of Mcl-1 with the Apogossypol derivative, BI-97C1, sensitizes human PCs to mda-7/IL-
24-mediated cytotoxicity, thus potentially augmenting the therapeutic benefit of this combinatorial 
approach toward PC.    
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Introduction 
Despite improvements in detection and treatment, PC remains the most common cancer and the 
second leading cause of cancer-related death in men in the USA (1). Because PC is a relatively slow-
growing disease, repeated systemic gene therapy applications alone or in combination with anti-
tumor chemotherapeutic agents over the life span of the patient may be required (1). 
Melanoma differentiation associated gene-7/Interleukin-24 (mda-7/IL-24), a novel member 
of the IL-10-related cytokine gene family, exhibits nearly ubiquitous anti-tumor properties in vitro 
and in vivo (2-4), which culminated in its successful entry into the clinic where safety and clinical 
efficacy was achieved (5). Unique therapeutic aspects of Ad.mda-7 lie in its selective induction of 
apoptosis in cancer cells, profound antitumor ‘bystander’ effect exerted by the secreted MDA-7/IL-
24 protein, and the ability of this novel cytokine to inhibit angiogenesis and provoke a potent anti-
tumor immune response (2). Upon ectopic expression of mda-7/IL-24 by an adenovirus, MDA-7/IL-
24 interacts with the endoplasmic reticulum (ER) chaperone protein BiP/GRP78 and initiates an 
”unfolded protein response (UPR)” in tumor cells that promotes apoptosis (6). Recently, we reported 
that in PC, ovarian and malignant gliomas, mda-7/IL-24-induced ER stress response produced 
apoptosis by suppressing expression of the anti-apoptotic protein Mcl-1 (4, 7, 8).  
In view of the essential roles of anti-apoptotic Bcl-2 family proteins in tumorigenesis and 
chemoresistance, efforts are focused on developing small molecule inhibitors of Bcl-2 family 
proteins as potential therapeutics for cancer (9). Unfortunately, due to the unique structure of Mcl-1 
as compared with Bcl-2 and Bcl-xL (9), currently employed inhibitors, such as ABT-737 or its 
clinical counterpart, ABT-263, display limited affinity for Mcl-1 (10) (Supplemental Figure 1). 
Using nuclear magnetic resonance (NMR) binding assays and computational docking studies, we 
have recently identified a series of new Apogossypol derivatives, compound 3 (BI-79D10) and 
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compound 11 (BI-97C1; Sabutoclax), with pan-Bcl-2-inhibitory potency (11, 12). BI-79D10 binds to 
Bcl-xL, Bcl-2, and Mcl-1 with IC50 values of 190, 360, and 520 nmol/L, respectively (13). BI-97C1 
is an optically pure individual Apogossypol derivative that retains all the properties of BI-79D10 
along with superior in vitro and in vivo efficacy (11).   
Because Mcl-1 is over-expressed in the majority of PCs (4), we hypothesized that 
suppressing Mcl-1 by treating human PC cells with BI-97C1 would sensitize them to mda-7/IL-24-
mediated cytotoxicity. Our data suggests that treatment with the combination regimen of mda-7/IL-
24 and BI-97C1 induces autophagy that facilitates apoptosis in association with up regulation of 
NOXA, accumulation of Bim, and activation of Bax and Bak. Treatment with mda-7/IL-24 and BI-
97C1 inhibited the growth of PC xenografts and suppressed PC development in an 
immunocompetent transgenic mouse model of PC.  
 
Results  
Mcl-1 promotes resistance to mda-7/IL-24-mediated apoptosis of human PC cells. Genetic and 
pharmacological inhibitors of Mcl-1 were used to determine if suppression of Mcl-1 expression 
sensitizes PC cells to mda-7/IL-24-mediated cytotoxicity. To facilitate delivery of mda-7/IL-24 to 
PC cells, which frequently contain reduced levels of Coxsackie Adenovirus Receptors (CAR), we 
employed a tropism-modified chimeric 5/3 adenovirus, Ad.5/3-mda-7 (14). siRNA-mediated 
reduction of Mcl-1 significantly sensitized PC3 cells to Ad.5/3-mda-7-induced apoptosis even at 
low doses (50 pfu/cell) (Figure 1A). On the other hand, treatment of PC3 cells with BI-79D10 or 
BI-97C1 resulted in reduced viability with an IC50 value of 750 nM for both compounds (Figure 
1B) while that of ABT-737 was 12 µM.   
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To evaluate the combinatorial effect of Mcl-1 inhibition and mda-7/IL-24 we treated PC3, 
DU-145, M2182 and normal, SV40 T-antigen-immortalized prostate epithelial cells (P69) with a 
sub-lethal dose of Ad.5/3-mda-7 (50 pfu/cell) and BI-79D10 at either 350 nM (at which 
concentration it inhibits Bcl-2 and Bcl- xL) or 520 nM (at which level it inhibits Mcl-1) (13). 
Treatment of PC3, DU-145 or M2182 cells with 350 nM of BI-79D10 in combination with 50 
pfu/cell of Ad.5/3-mda-7 had a minimal effect on promoting apoptosis, whereas infection with 
Ad.5/3-mda-7 (50 pfu/cell) and treatment with 520 nM of BI-79D10 profoundly promoted 
apoptosis (Figure 1C). In contrast, the combination exerted little to no toxicity in normal P69 cells, 
indicating cancer-specific activity (Figure 1C). Furthermore, the combination also showed a greater 
than additive induction of apoptosis in mda-7/IL-24-resistant DU-145 cells that stably over-express 
Bcl-2, Bcl-xL or Mcl-1  (Du-bcl-2, Du-bcl-xL and Du-Mcl-1-8, respectively) (4, 15) (Figure 1D). A 
similar enhanced induction of apoptosis was observed in these therapy-resistant prostate cancer cell 
lines by treatment with Ad.5/3-mda7 and BI-97C1 (Figure 2A and 2B). BI-97C1 is an optically 
purified small molecule suitable for clinical use (11). Induction of apoptosis was observed with as 
low as 10 pfu/cell of Ad.5/3-mda-7 in combination with BI-97C1 (Figure 2A). Similarly, BI-97C1 
potently induced apoptosis of PC3 cells with an IC50 of approximately 500 nM in combination with 
Ad.5/3-mda-7 (50 pfu/cell) (Figure 2B). A time course analysis revealed that 48 h was required for 
the combination of Ad.5/3-mda-7 and BI-97C1 to significantly promote apoptosis of human PC 
cells (Figure 2C). Treatment of human PC cells with Ad.5/3-mda-7 and BI-97C1 resulted in PARP 
cleavage, activation of Caspase-3, cytosolic release of cytochrome c and Smac/DIABLO, as well as 
inactivation of cell proliferation signals, i.e., AKT and ERK (Figure 2D to 2F).  
Bim and NOXA activity are required for BI-97C1/mda-7-IL-24-mediated Bak- and Bax-
dependent apoptosis. To analyze the involvement of mitochondrial pathway of apoptosis (16), PC3 
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cells were treated with BI-97C1 (520 nM) and Ad.5/3-mda-7 (50 pfu/cell) and expression of 
Bak/Bax conformational changes (detected by immunoprecipitation using antibodies that 
specifically recognize activated Bak or Bax) (16) and intracellular Bax localization were assessed. 
Treatment of PC3 with BI-97C1 and Ad.5/3-mda-7 moderately elevated expression of total Bax and 
Bak compared to either single agent alone (Figure 3A). Treatment with the combination of BI-97C1 
and Ad.5/3-mda-7 induced Bak or Bax conformational changes significantly greater than either 
agent alone (Figure 3B). Similarly, combination treatment dramatically increased mitochondrial 
translocation of Bax (Figure 3B) and Bak/Bax association (Figure 3C). Transient shRNA-mediated 
knockdown of Bax and Bak promoted resistance to BI-97C1/mda-7/IL-24-mediated toxicity (Figure 
3D).  
Considering the potential roles that the BH3-only proteins, NOXA and Bid play in apoptosis 
induced by various stimuli (17), expression and/or phosphorylation of these proteins were examined 
following combination treatment in PC3 cells. After 48 h of combined treatment, we observed a 
significant increase in NOXA expression, Bim accumulation, and suppression of Bid and p-Bad 
expression compared with treatment with either agent alone (Figure 4A). When PC3 cells were 
transiently transfected with shRNA against NOXA or Bim, a significant degree of resistance 
towards BI-97C1/mda-7-IL-24-mediated apoptosis was observed (Figure 4B and 4C). Earlier we 
reported that mda-7/IL-24 induces ER stress by activation of PERK (PKR-like ER-localized eIF2α 
kinase) (2). We observed that ER stress generated by mda-7/IL-24 was enhanced by combined 
treatment with BI-97C1 (Figure 4D: Left panel). Interestingly, inhibition of PERK by a dominant 
negative construct in PC3 cells protected them from cytotoxicity of the combination treatment 
accompanied by a reduction in Bim accumulation and PARP cleavage, but with minimal effects on 
elevated NOXA expression (Figure 4D).   
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Induction of Autophagy by the combination of mda-7/IL-24 and BI-97C1 precedes apoptosis. 
Autophagy is usually initiated in response to increased metabolic requirements during cellular stress 
induced by therapeutic treatments (18). For that reason, we evaluated autophagy in response to 
treatment with mda-7/IL-24 and BI-97C1. Induction of LC3 in autophagic vacuoles was determined 
by transient transfection of PC3 cells with a baculovirus-expressing RFP fused with LC3. 
Treatment with BI-97C1 or mda-7/IL-24 alone resulted in a significant increase in the LC3-RFP 
signal and LC3-II expression that was further augmented by combination treatment (Figure 5A). 
Because mda-7/IL-24 selectively targets transformed cells, we transfected MEFs with a human 
pcDNA3.1-H-ras construct. Human H-ras transfected Bax-/-Bak-/- MEFs were resistant to mda-
7/IL-24 + BI-97C1-induced cytotoxicity compared to wild type MEFs, indicating that cell death 
induced by the combination is due to apoptosis, not autophagy (Figure 5B). On the other hand, we 
also detected a slight induction of autophagy in Bax-/-Bak-/- MEFs as compared to wild type MEFs 
following combination treatment (Supplementary Figure 3C). These results suggest that autophagy 
induced by the combination treatment might protect cells from initial stress followed by a switch to 
apoptosis at a later time point. Furthermore, the increase in LC3-RFP signal and expression of LC3-
II was maximum at 24 h and decreased by 48 h of post treatment, whereas apoptosis, detected by 
TUNEL assay and PARP cleavage, was evident at 48 h, but not at 24 h post-treatment (Figure 5C 
and 5G). Notably, we observed that down-regulation of the essential autophagy genes Beclin-1 or 
ATG5 (to a lesser extent) (but not ATG7) by siRNA reduced the cytotoxicity of the combination 
effect (Figure 5D). This finding was supported by the observation that 24 h after combination 
treatment, the interaction between Mcl-1 and Beclin-1 was disrupted (Figure 5E). The switch 
between autophagy and apoptosis is a complex process that is currently poorly understood (18). 
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Previously, it was found that in a cellular model system where autophagy precedes apoptosis, IL-3 
depletion of Ba/F3 cells caused caspase-mediated cleavage of Beclin-1 and PI3KC3 (18). 
Interestingly, cleavage of Beclin-1 during apoptosis not only inactivates its autophagic function, but 
also generates a Beclin-1-derived fragment that translocated to the mitochondria and enhanced the 
release of cytochrome c and hence augmented apoptosis (18). We also observed that 48 h after 
combined treatment, activation of caspase-3 was associated with cleavage of Beclin-1 (Figure 5F). 
When Caspase-3 activity was inhibited using a pharmacological inhibitor, PC3 cells developed 
resistance towards the cytotoxicity induced by the combination of Ad.5/3-mda-7 and BI-97C1 
(Figure 5F).  
Combination treatment with mda-7/IL-24 and BI-97C1 potentiates inhibition of human prostate 
tumor growth in vivo in immune deficient and immune competent animals. To test efficacy in 
vivo, we performed studies that utilized two animal models, one employing immune deficient 
athymic nude mice xenografted with human prostate tumor cells (M2182) (11) and one using a 
spontaneous immunocompetent transgenic mouse model of prostate cancer (the Hi-Myc mouse) 
(19). Initial studies were performed in nude mice bearing subcutaneous M2182 human prostate 
tumors established on both flanks that stably express luciferase (M2182-Luc). Mice were treated, 
when tumor size was ~100 mm3, using a sub-optimal dose of 0.5 X 108 pfu per injection of Ad.5/3-
vec or Ad.5/3-mda-7 (7 injections). BI-97C1 was injected intraperitoneally (i.p.) (11) either at 
1mg/kg or 3 mg/kg 3X a week for the 3-week duration of the study (9 injections). Tumor growth 
was markedly inhibited by combination treatment compared to treatment with either agent alone 
(Figure 6A). Combined treatment of Ad.5/3-mda-7 and BI-97C1 (3 mg/kg) significantly reduced 
Ki-67 expression and increased TUNEL signal compared to treatment with either agent alone 
(Figure 6B). BI-97C1 was observed to be non-toxic to athymic nude mice (NCRnu/nu) when 
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injected intraperitonially (up to 10 mg/kg) or when injected intravenously (25 mg/kg) 
(Supplemental Figure 4 and Supplemental Tables 1 and 2). 
Next, we tested the efficacy of Ad.5/3-mda-7 and BI-97C1 in a spontaneous model of 
prostate cancer, the Hi-Myc mouse (19). For optimal therapeutic outcome for adenocarcinoma, we 
began treatment at 22 weeks of age. The ability to deliver adenoviruses systemically is limited by 
sequestering of the virus in the liver and clearance of the virus by the immune system. We have 
developed a novel strategy to circumvent both of these problems that employs microbubbles treated 
with complement and targeted release of the therapeutic virus at the tumor site using ultrasound, an 
approach referred to as microbubble-targeted ultrasound destruction (UTMD) (20). In this context, 
systemic and targeted delivery of mda-7/IL-24 to the prostate of Hi-Myc mice was achieved by 
intravenous injection of complement-treated microbubble (MB) encapsulated Ad.5/3-mda-7 
followed by sonoporation in the prostatic area, UTMD (20). A total of 9 tail vein injections of 
MB/Ad.5/3-mda-7 were administered over a 4-week period. BI-97C1 was administered 
intraperitoneally (i.p.) at 3 mg/kg 3X a week throughout the study. The size of the prostates of Hi-
Myc mice treated with the combination of Ad.5/3-mda-7 and BI-97C1 were significantly reduced 
compared to treatment with either agent alone or the vehicle ( and Ad.5/3-vec) (Figure 6C). 
Decreased Ki67 and increased TUNEL expression accompanied tumor growth inhibition was 
observed in sections of the prostates of Hi-myc mice with Ad.5/3-mda-7 and BI-97C1 as compared 
to each single agent alone (Figures 6C and 6D).  
 
Discussion  
Even though mda-7/IL-24 can induce apoptosis in diverse human cancers, it is apparent that some 
subsets of cancer cells are relatively resistant to this therapy (2). One mode of resistance to mda-
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7/IL-24-based therapies occurs through elevated expression of either Mcl-1 or Bcl-xL, which 
promotes resistance to mda-7/IL-24-induced apoptosis (4, 15). Exposure of PC cells to mda-7/IL-24 
moderately down-regulates Bcl-xL, whereas this treatment completely extinguishes Mcl-1 
expression, suggesting that the Mcl-1 gene may be more relevant in conferring resistance to mda-
7/IL-24-mediated cytotoxicity and may provide a more appropriate target for enhancing sensitivity 
to this therapeutic cytokine. To test this hypothesis, we inhibited Mcl-1 expression by siRNA in 
Du-Bcl-xL, which are resistant to Ad.mda-7-mediated apoptosis (15). Inhibiting Mcl-1 expression 
was able to overcome resistance of Du-Bcl-xL cells to Ad.mda-7-induced apoptosis. In contrast, 
siRNA-mediated reduction of Bcl-xL in mda-7/IL-24 resistant Du-Mcl-1-8 cells (4) did not sensitize 
them to Ad.mda-7-induced apoptosis (Supplemental Figures 2A and 2B). These findings indicate 
that Mcl-1, rather than Bcl-xL, plays a more definitive role in generating resistance to mda-7/IL-24-
induced apoptosis. Treatment with novel BI-97C1 in nanomolar range is sufficient to sensitize mda-
7/IL-24-resistant cells, which over-express Bcl-2, Bcl-xL or Mcl-1, to mda-7/IL-24-dependent 
apoptosis. Because the Bcl-2/Bcl-xL inhibitor ABT-737/ABT-263 does not inhibit Mcl-1, treatment 
with ABT-737 failed to sensitize PC cells to mda-7/IL-24-induced apoptosis (Supplemental Figure 
3A and 3B).  
Based on the present data, a hypothetical model is proposed by which mda-7/IL-24 and BI-
97C1 cooperate to induce Bim- and NOXA-dependent intrinsic apoptosis (Figure 6E). Although the 
mechanism by which Bim promotes apoptosis remains unclear, it has been shown that up-regulation 
of Bim results in the release of pro-apoptotic multidomain Bcl-2 family members Bak and Bax. 
Once activated Bax and Bak permeabilize the mitochondrial membrane, thereby facilitating the 
release of apoptotic inducing factors such as cytochrome c, AIF, and Smac/DIABLO (16). Evidence 
for direct activation of Bax by Bim also exists (21). Similarly, inhibition of Mcl-1 by treatment with 
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BI-97C1 results in up regulation of NOXA, which may lead to not only activation of Bak (16), but 
also the ability of Mcl-1 to efficiently sequester Bim (22). Alternatively, activation of Bak/Bax by 
BI-97C1 and mda-7/IL-24 may inhibit Bcl-2 and Bcl-xL. It is important to note that in the present 
combination studies, the concentration of BI-97C1 employed was 520 nM, which also inhibits Bcl-
2 and Bcl-xL. Our data also suggest that at early times, autophagy induction by the combination 
may provide an initial cytoprotective response, based on evidence that knocking down Beclin1 or 
ATG5 expression protected cells from mda-7/IL-24/BI-97C1 toxicity. On the other hand, at later 
times (e.g., 48 h) caspase-mediated cleavage of Beclin-1 may instead augment apoptosis rendered 
by the combination regimen (Figure 6E). 
In summary, the present study highlights the noteworthy potential of a combinatorial 
approach involving mda-7/IL-24, a broad-acting anticancer gene, and BI-97C1, which targets Mcl-
1, to sensitize PC to mda-7/IL-24-mediated cytotoxicity, thereby enhancing therapeutic efficacy. 
Based on the safety profile of the individual agents, and the fact that mda-7/IL-24 is now in the 
clinic and has been shown to be safe and efficacious, this novel combinatorial approach may be 
translatable into the clinic for the treatment of advanced PC in the near future.  
  
Materials and Methods 
Cells, stable clones, culture conditions and adenoviral constructs. P69 and Human PC cells 
M2182, DU-145 and PC3, Wild type (wt), and Bax-/-/Bak-/- MEF were cultured as described (15). 
DU-145 clones stably overexpressing Bcl-2, Bcl-xL, Mcl-1 and M2182-Luc were generated as 
described (4, 15).  
Assessment of cell viability, cell death and apoptosis. Apoptotic cells were identified and 
quantified by Annexin V–fluorescein isothiocyanate staining and DeadEnd Colorimetric TUNEL 
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Assay kit (Promega, Madison, WI) (15), and cell death was quantified by trypan blue dye exclusion 
assays (4) and cell viability was measured by MTT assays (14).  
Transient transfections. Transfections were carried out using Lipofectamine 2000 (Invitrogen) 
according to the manufacturer’s protocol with different plasmids for 24 h before treatment, 100 nM 
SMARTpool Mcl-1, Bcl-xL siRNAs or control siRNA (siControl) (Dharmacon, Inc.), siATG5, 
siBeclin-1, siATG-7 (Santa Cruz Biotechnology Inc) (23, 24). 
Immunoprecipitation and immunoblotting. Immunoprecipitation and immunoblotting were 
performed as previously described (4). The primary antibodies used in this study were as follows: 
Mcl-1, BiP/GRP78, Bak, Phosho-PERK, Smac/DIABLO, GADD153, cytochrome c, NOXA (Santa 
Cruz Biotechnology Inc); PARP, Bcl-xL, total and p-ERK1/2 (Thr-202/Tyr-204), total and p-Akt 
(Thr-183/Tyr-185), Bid, p-Bad (Cell Signaling Technology, Danvers, MA); MDA-7/IL-24 
(GenHunter Corporation, Nashville, TN); anti-EF1α (Upstate Biotechnology, Lake Placid, N.Y); 
and GRP94 (Sigma). Bax, Bim (BD Pharmigen). LC3, ATG-5, ATG-7, Beclin-1 and Caspase-3 
(Novus Biologicals). zVAD-FMK (Enzyme Systems Products). Cisplatin  (Bristol-Meyer Squibb 
Oncology NY, USA). ABT-737 (SYNthesis Med Chem, China). Luciferin (Roche Applied 
Science).  
Detection of Bak and Bax activation. Detection of Bax and Bak activation was performed by flow 
cytometry as described (16). For Bax translocation studies, mitochondrial and cytosolic fractions 
were prepared by using the mitochondria fractionation kit (Active Motif) according to the 
manufacturer’s protocol.  
Human prostate cancer xenografts. M2182-Luc (1 X 106) cells were injected s.c. in the left and 
right flank of male athymic nude mice as described (11). After establishing visible tumors of ~100-
mm3, intratumoral injections of Ad.5/3-vec or Ad.5/3-mda-7 were given to the tumors on the left 
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flank at a dose of 0.5 X 108 pfu in 100 µl. The injections were given 3X the first week and then 2X 
a week for two more weeks for a total of seven injections. BI-97C1 (dissolved in 
ethanol/Cremophor EL/saline = 10:10:80) was injected i.p. at a sub-toxic level (11) either at 1 
mg/kg or 3 mg/kg 3X a week throughout the study (total 9 injections). 
Preparation of microbubbles (MBs), ultrasound (US) platform and ultrasound-targeted 
microbubble destruction (UTMD). Hi-Myc (19) mice were obtained from the Mouse Repository at 
NCI Frederick, MD, USA and genotyping was done based on the primer information available in 
NCI. Preparation of MBs followed by UTMD for delivery of mda-7/IL-24 expressing Ads has been 
described (20). The mice were divided into four groups: I) Ad.5/3-vec, II) Ad.5/3-vec + BI-97C1, 
III) Ad.5/3-mda-7, and IV) Ad-5/3-mda-7 + BI-97C1 group. Ultrasound (sonoporation) was 
performed (20) in the ventral side of mice in the prostatic area. BI-97C1 was administered 
intraperitoneally at a dose level of 3 mg/kg 3X a week for the duration of the study (total 9 
injections).  
Immunohistochemical staining. For immunohistochemical analysis, formalin-fixed and paraffin-
embedded specimens of 3–4-µm thickness were sectioned and stained with ant-MDA-7/IL-24 and 
Ki-67 as described (4).  
Monitoring autophagy. For detection of autophagy, PC3 cells were infected with BacMam LC3B-
RFP baculovirus reagent (PremoTM Autophagy Sensor Kit, Invitrogen),. For staining cytoskeleton, 
MAP4-GFP (Cellular Lights MAP4-GFP, Invitrogen) transduction reagents were used and after 
treatment samples were analyzed by confocal laser-scanning microscope (Zeiss 510 Meta confocal 
imaging system). 
Molecular Modeling and NMR studies. A 15N-labeled Mcl-1 sample was prepared and NMR 
measurements of Mcl-1 and compound interactions were carried out using a series of 1H-15N HSQC 
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spectra as described (9). Molecular modeling studies were conducted on a Linux workstation and a 
64 3.2-GHz CPUs Linux cluster. Docking studies were performed using the crystal structure of 
Mcl-1 in complex with a BH3 mimetic ligand (Protein Data Bank code 2NL9). 
Statistical analysis. Data are represented as the mean ± S.D. and analyzed for statistical 
significance using one-way ANOVA followed by Newman-Keuls test as a post hoc test.  P value of 
<0.05 was considered significant. 
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Figure Legends 
 
 
Figure 1:  Genetic or pharmacological knockdown of Mcl-1 sensitizes PC to mda-7/IL-24-
mediated apoptosis: A) PC3 cells were transiently transfected with indicated siRNA for 24 h 
(inset) followed by infection with Ad.5/3-mda-7 at different pfu/cells for an additional 48 h, and % 
of apoptotic cells was determined. S.D. (n = 3). * indicates P <.01. B) PC3 cells were exposed to 
the indicated concentrations of BI-79D10, BI-97C1 or ABT-737 for 48 h after which % of cell 
survival was evaluated. Bars, S.D. (n = 3). C) DU-145, PC3, M2182 and P69 cells were infected 
with 50 pfu/cell of Ad.5/3-vec or Ad.5/3-mda-7 for 6 h and then treated with indicated 
concentrations BI-79D10 for 48 h and apoptosis was monitored. S.D. (n = 3), *(M2182), ** (PC3) 
and *** (DU-145) indicates P <.01 for BI-97C1 and Ad.5/3-mda-7 treated group. D) mda-7/IL-24-
resistant DU-145 cells stably expressing Bcl-xL, Bcl-2 and Mcl-1 were treated as in A and apoptosis 
was evaluated. S.D. (n = 3) * (Du-bcl-2), ** (Du-bcl-xL) *** (Du-Mcl-1-8) indicates P <.01 for BI-
97C1 and Ad.5/3-mda-7 treated group.  
 
Figure 2: BI-97C1 and mda-7/IL-24 cooperate to induce death in prostate cancer cells:  A) 
PC3 cells were infected with indicated doses of Ad.5/3-mda-7 for 6 h and then treated with DMSO 
or BI-97C1 for 48 h. B) PC3 cells were infected with Ad.5/3-vec or Ad.5/3-mda-7 for 6 h and then 
treated with indicated concentrations of BI-97C1 for 48 h. C) PC3 cells were infected with Ad.5/3-
vec or Ad.5/3-mda-7 for 6 h and then treated with DMSO or 520 nM of BI-97C1 for the indicated 
time. In A, B and C, % of apoptosis was evaluated. Bars represent S.D. (n = 3). D) PC3 cells were 
infected with Ad.5/3-vec or Ad.5/3-mda-7 for 6 h and then exposed indicated concentrations of BI-
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97C1 for 48 h after and Western blotting was performed with indicated antibodies. E) PC3 cells 
were treated as mentioned in D and cytosolic protein fractions were isolated and Western blotting 
was performed F) PC3 cells were treated as mentioned in D and Western blotting was performed.  
 
Figure 3: Combination of mda-7/IL-24 and BI-97C1 results in Bak and Bax conformational 
change, whereas knockdown of these molecules markedly attenuates apoptosis. A) PC3 cells 
were infected with 50 pfu/cell of Ad.5/3-vec or Ad.5/3-mda-7 for 6 h and then exposed to DMSO 
or BI-97C1, for 48 h. Protein lysates were collected and Western blotting was performed. B) PC3 
Cells were treated as mentioned in A and then activated Bak and Bax proteins were monitored as 
described in the Material and Methods section (top panel). Alternatively, cytosolic and 
mitochondrial fractions were separated and subjected to Western blotting analysis (bottom panels). 
C) PC3 cells were treated as mentioned in panel B and subjected to immunoprecipitation using anti-
Bak antibodies. D) PC3 cells transiently transfected with shGFP, shBax or shBak (insert) for 24 h 
as described in Materials and Methods section and were treated as described in A. Cell death was 
determined using trypan blue dye exclusion. S.D. (n=3), * indicates P <.01.	  
 
Figure 4:  Bim and NOXA play critical roles in Bax- and Bak-mediated cytotoxicity induced by 
mda-7/IL-24 and BI-97C1. A) PC3 cells were infected with Ad.5/3-vec or Ad.5/3-mda-7 for 6 h 
and then treated with indicated concentrations of BI-97C1 for 48 h and Western blotting was 
performed. B) PC3 cells transiently transfected with shGFP, shBim or shNOXA (insert) and treated 
as described in A. Cell death was determined using trypan blue dye exclusion. S.D. (n=3). * 
indicates P <.01. C) Left and Right panel: PC3 cells were treated as mentioned in panel B after 
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which cell lysates were subjected to determine Bax conformation analysis as indicated in Materials 
and Methods D) Left Panel: PC3 were treated as mentioned in A and Western blotting was 
performed. Right Panel: PC3 cells transiently transfected with pcDNA3.1 or pcDNA3.1DNPERK 
(insert) as described in Materials and Methods were treated as mentioned in A and cell death was 
determined using trypan blue dye exclusion assay (lower panel) and Western blotting was 
performed. S.D. (n=3). * Significantly lower vs pcDNA3.1 transfected cells (P <0.01).	  
 
Figure 5:  Autophagy induced by the combination of mda-7/IL-24 and BI-97C1 progresses to 
apoptosis by caspase-dependent cleavage of Beclin-1: A) Upper panel: PC3 cells were infected with 
LC3-RFP and MAP-4-GFP. After incubation 12 h, the cells were infected with 50 pfu/cell of Ad.5/3-
vec or Ad.5/3-mda-7 for 6 h and then exposed to BI-97C1. Localization of LC3 (red) and the 
cytoskeleton (green) were examined by confocal laser microscopy (magnification x 100). Lower 
panel: To quantitate endogenous LC3II the indicated cells were treated as described above in upper 
panel and LC3 expression was analyzed by Western blotting. B) Wild type and Bax-/-Bak-/- double 
knockout MEFs were transiently transfected with pcDNA3.1H-ras vector. After 24 h cells were treated 
as in A and cell death was measured by Trypan blue dye exclusion assay. S.D. (n = 3). C) Localization 
of LC3 (red) and cytoskeleton (green) were examined as described in A after PC3 cells were infected 
with 50 pfu/cell of Ad.5/3-vec or Ad.5/3-mda-7 for 6 h and then exposed to 520 nM of BI-97C1 for 
indicated times. Apoptosis was determined by TUNEL staining. D) PC3 cells were transfected with 
the indicated siRNAs. Following 24 h incubation, cells were treated as described in A. Cell death 
(right panel) was determined by trypan blue dye exclusion. S.D. (n=3). Western blotting was 
performed with indicated antibodies (left panel). E) PC3 cells were treated as described in A for 24 h. 
Cell lysates were immunoprecipitated using anti-Beclin-1 antibody and then immunoblotted with anti-
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Mcl-1 antibody or vice versa. F) Left panel: PC3 cells were treated as described in A and Western 
blotting was performed. Right panel: PC3 cells were treated as described in A in the presence or 
absence of 25 µM of z-VAD-FMK. Cell death was measured by trypan blue dye exclusion. S.D. 
(n=3). G) Temporal induction of PARP cleavage and LC3-II expression by Western blotting following 
infection with 50 pfu/cell of Ad.5/3-mda-7 and BI-97C1. 
 
Figure 6: The combination regimen of mda-7/IL-24 and BI-97C1 additively inhibits prostate 
tumor growth in athymic and immunocompetent mice, and a hypothetical model of the 
combination regimen: A) Athymic nude mice-bearing M2812 xenografts stably expressing luciferase 
in both right and left flanks were treated as indicated in the Materials and Method section. Tumor 
growth was visualized by bioluminescence measured by the Xenogen imaging system. B) At the end 
of the study in panel A, tumors were harvested and stained for Ki-67, MDA-7/IL-24 and TUNEL. C) 
Left Panel: The prostatic region of male Hi-Myc mice were sonoporated for 10 min following tail-vein 
injection of the indicated complement-treated microbubble/Ad complexes and treated as described in 
the Materials and Method section.  At the end of the experiment the mice were sacrificed and the 
prostates were harvested, weighed and photographed. Right panel: Hi-Myc mice were treated as 
described above and proliferative index was measured by Ki-67 staining of paraffin-embedded 
sections of prostate from treated mice as described in panel D, S.D. (n=7) D) Hi-Myc mice were 
treated as described in panel C, paraffin-embedded sections obtained from the prostate were analyzed 
by immunohistochemistry using ant-Ki-67 and anti-MDA-7/IL-24 antibodies. Apoptosis in the 
prostate sections was detected by TUNEL assay. E) Hypothetical model of action for the combination 
regimen of mda-7/IL-24 and BI-97C1 (Sabutoclax) in prostate cancer cells.  
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Figure 1 
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Figure 2 
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Figure 3 
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Figure 4 
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Figure 5 
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Figure 6 
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Fig. S1. Binding studies to Mcl-1. (A) Chemical structure of BI-97C1 (also called Sabutoclax), 
BI-79D10, and ABT-737. Compounds BI-79D10 and BI-97C1 were 
synthesized as described previously by Wei et al. (1) and Wei et al. (2), respectively. Compound 
purity for BI-97C1 (99%) was verified by HPLC. ABT-737 was 
purchased from SYN|thesis Med Chem. (B) Docked structure of BI-97C1 into the BH3 binding 
groove of Mcl-1. The structure of BI-97C1 is represented in ball 
and stick and colored in atom types. The surface of Mcl-1 (PDB code: 2NL9) is calculated via 
MOLCAD (Tripos) and colored according to cavity depth: blue, 
shallow; yellow, deep. (C) Superimposition of HSQC spectra of Mcl-1 (0.1 mM) recorded in the 
absence (red) and presence (blue) of ABT737 (0.2 mM). The 
spectra are nearly identical, indicating no significant binding to Mcl-1 by ABT-737 under these 
experimental conditions. (D) Superimposition of HSQC spectra of 
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Mcl-1 (0.1 mM) in the absence (red) and presence (green) of BI-97C1 (0.2 mM). Several 
changes can be observed that can be mapped to the BH3 binding groove 
of Mcl-1. 
1. Wei J, et al. (2010) BI-97C1, an optically pure Apogossypol derivative as pan-active inhibitor 
of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins. J Med Chem 53: 
4166–4176. 
2. Wei J, et al. (2009) Apogossypol derivatives as antagonists of antiapoptotic Bcl-2 family 
proteins. Mol Cancer Ther 8:904–913.  
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Fig. S2. Mcl-1 but not Bcl-xL plays a critical role in mda-7/IL-24 mediated cytotoxicity in PC. 
(A) Left: A stable clone (Du-Bcl-xL) of DU-145 cells ectopically expressing Bcl-xL (Inset) cells 
were transfected with control or Mcl-1 siRNA and 48 h later whole cell lysates were subjected to 
Western blotting analysis to quantify Mcl-1 expression. Right: After transfection with control 
siRNA or Mcl-1 siRNA, cells were infected with 100 pfu/cell of Ad.vec or Ad.mda-7 for 48 h, 
after which the percentage of apoptosis was determined by flow cytometry after AnnexinVFITC/ 
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PI staining. Results are the mean + SD (n = 3) from three independent studies. (B) Left: Stable 
clone of DU-145 cells ectopically expressing Mcl-1 (Du-Mcl-1-8) (Inset) were transfected with 
the control or Bcl-xL siRNA and 48 h later whole cell lysates were subjected to Western blotting 
analysis to quantify Bcl-xL expression. Right: 48 h after transfection with control siRNA or Bcl-
xL siRNA, cells were infected with the 100 pfu/cell of Ad.vec or Ad.mda-7 for an additional 48 
h, and the percentage of apoptosis was determined by flow 
cytometry after AnnexinV-FITC/PI staining. Results are the mean + SD (n = 3) from three 
independent studies. 
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Fig. S3. BI-97C1 but not ABT-737 cooperates with mda-7/IL-24 to show enhanced cytotoxic 
effect in PC. (A) M2182 cells were infected with 50 pfu/cell of Ad.5/3-vec or Ad.5/3-mda-7 for 
6h, after which the cells were exposed to 1 µM of ABT-737 or BI-97C1 (also called Sabutoclax) 
and cell viability was measured by MTT assay as described in Materials and Methods. Bar, SD 
(n = 3). (B) M2182 cells were treated as mentioned in A and the lysates were collected to 
perform Western blotting with indicated antibodies. (C) Wild-type and Bax/Bak-negative MEF 
(DKO) cells were infected with Ad.5-vec or Ad.5-mda-7 for 6 h and then treated with indicated 
concentrations of BI-97C1 for 48 h. Western blotting was performed with the indicated 
antibodies. 
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Fig. S4. Tolerance level of BI-97C1 (also called Sabutoclax) in athymic nude mice (NCRnu/nu). 
Six- to 8-wk-old female athymic nude mice were acquired from Harlan Laboratories. Groups of 
three female mice were treated on d 0, 2, 6, 8, 10, and 13 as indicated by arrows. i.v. or i.p. doses 
of vehicle (CT) or BI-97C1 were administered at concentrations shown. Vehicle consisted of 
84% PBS/8% Tween-20/8% DMSO. Data reflects survival. 
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Using a new serotype chimera Cancer Terminator Virus (Ad.5/3-CTV) to 
improve the efficiency and specificity of prostate cancer gene transfer and 
therapy  
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Abstract  
Gene therapy using Conditionally Replication-Competent Adenoviruses (CRCAs) is being 
examined as a potential strategy for treating prostate cancer (PC). We have earlier successfully 
constructed and evaluated a CRCA, termed Cancer terminator Virus (CTV), in which the 
adenoviral replication is controlled by the cancer selective promoter of the Progression Elevated 
Gene-3 (PEG-3) and which simultaneously expresses melanoma differentiation associated gene-
7/interleukin-24 (mda-7/IL-24) from the E3 region of the adenovirus.  The CTV was constructed 
on serotype 5 background (Ad.5-CTV) and thus its infectivity is dependent on Coxsackie-
adenovirus Receptors (CARs). Many tumor types including PC show a downregulation in CAR, 
thereby limiting therapeutic gene transduction. Using serotype chimerism, we generated a new 
CTV (Ad.5/3-CTV) in which the Ad.5 fiber knob is replaced by Ad.3 fiber knob thus facilitating 
infection via Ad.3 receptors in a CAR-independent manner. The current study evaluated Ad.5/3-
CTV, in comparison to Ad.5-CTV, in low CAR human PC, demonstrating higher efficacy in 
inhibiting cell viability in vitro as well as inhibiting tumor growth in nude mice xenograft model 
and spontaneously induced PC in Hi-myc transgenic mice in vivo. Ad.5/3-CTV exerted a marked 
anti-tumor ‘bystander’ effect in vivo thus establishing its therapeutic utility.  Considering the fact 
that non-replicating Ad.5-mda-7 showed significant responses in a Phase I clinical trial for solid 
tumors, Ad.5/3-CTV might exert significantly enhanced therapeutic benefit and clinical efficacy. 
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Introduction 
Prostate Cancer (PC) is the most frequently diagnosed cancer and is the second leading cause of 
cancer death among men in the US (1). It is estimated that 217,730 new PC cases were 
diagnosed in 2010 alone. Patients with localized disease may be treated with surgery or radiation, 
whereas the treatment for patients with metastatic disease is purely palliative. Current therapies 
include hormonal therapy, radiotherapy and cytotoxic chemotherapeutic agents (2). These 
therapies are inefficient on the overall survival of patients. Therefore a novel, more efficient and 
innovative treatment is needed, and genetic therapies represent promising approaches for the 
treatment of this neoplasm. 
Using subtraction hybridization combined with induction of cancer cell terminal differentiation, 
our laboratory cloned melanoma differentiation-associated gene-7/interleukin-24 (mda-7/IL-24) 
(3), a novel member of the IL-10–related cytokine gene family (4). Subsequent studies 
documented that mda-7/IL-24 has almost ubiquitous antitumor properties in vitro and in vivo, 
leading to its entry into the clinic, where its safety and clinical efficacy, when administered by 
adenovirus (Ad.mda-7; INGN 241), was observed in a phase I clinical trial in humans with 
advanced carcinomas and melanomas (5, 6). Its mode of action involves preferential induction of 
apoptosis in cancer cells while exerting no discernible toxic effects toward normal cells (7, 8) by 
eliciting potent “antitumor bystander activity” as a consequence of autocrine and paracrine 
secretion (8-10). 
Since PC is commonly a relatively slow-growing disease, it may require repeated gene therapy 
treatments, with single or multiple genes, over the lifespan of the patient. Conditionally 
replication-competent adenoviruses (CRCAs) provide a valuable potential tool for gene therapy. 
Using subtraction hybridization we cloned a novel rodent gene, PEG-3, in the context of tumor 
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progression in transformed rat embryo cells (11). PEG-3: (i) displays elevated expression as a 
function of oncogenic transformation (by diverse oncogenes) (11, 12); (ii) induces an aggressive 
cancer phenotype without promoting transformation when expressed in normal cells (13, 14); 
and (iii) gene promoter (PEG-Prom) has been isolated and shown to display elevated expression 
in both rodent and human tumors (including PC), with negligible expression in normal cells 
(including human prostate epithelium) (15-17).  Considering the cancer-specific expression 
aspects of the PEG-Prom, we constructed a bipartite serotype 5 CRCA (CRCA, called a cancer 
terminator virus – Ad.5-CTV) in which the expression of E1A and E1B genes of Ad, necessary 
for replication, is regulated by the PEG-Prom (18). This novel Ad.5-CTV also expresses mda-
7/IL-24 from the E3 region (Ad.PEG-E1A-mda-7). The ability of Ad.5-CTV to infect and 
express MDA-7/IL-24 in prostate cancer cells depends on the presence of Coxsackie-Adenovirus 
Receptors (CAR) on their surface. Ad.5-CTV is capable of efficiently infecting high CAR 
receptor cells, such as DU-145, whereas it fails to efficiently infect and consequently efficiently 
express MDA-7/IL-24 in low CAR receptor cells, such as PC-3. An approach to circumvent the 
low efficiency of Ad.5 infection of tumor cells involves ‘tropism modification’ in which virus 
capsid proteins that normally associate with CAR are modified, permitting CAR-independent 
infectivity of tumor cells. Studies using various tumor cell types have shown that inclusion of the 
infective type 3 Ad sequence within the Ad type 5 virus knob (Ad.5/3 recombinant virus) 
promotes viral infectivity in tumor cells showing reduced or no CAR expression (19-21). It 
should be noted that Ad.5/3 also infects high CAR-expressing tumor cells with equal efficacy 
when compared with Ad.5, thereby providing an expanded scope of utility for Ad.5/3, in both 
low and high CAR-expressing tumor cells. This study explored the efficiency of Ad.5/3-CTV  
infection of low CAR tumor cells by using a recombinant Cancer Terminator Virus Ad.5/3-CTV 
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(Fig. 1) in which the virus capsid proteins that normally associate with CAR are modified, 
permitting CAR-independent infectivity of tumor cells. This study explored the efficacy of a 
tropism-modified CRCA cancer gene therapy approach for eradicating low CAR prostate cancer 
cells. We showed that in low CAR PC3 cells Ad.5/3-CTV is more efficient than Ad.5-CTV in 
delivering transgene (mda-7/IL-24), infecting tumor cells, expressing MDA-7/IL-24 protein, 
inducing cancer-specific apoptosis, inhibiting in vivo tumor growth and exerting an antitumor 
‘bystander’ effect in a nude mouse human prostate cancer xenograft and suppressed PC 
development in an immunocompetent transgenic mouse model of PC model. 
 
Results 
Ad.5/3-CTV enhanced mda-7/IL-24 expression and inhibition of cell viability in low CAR 
prostate cancer cells. The schema for construction of Ad.5/3-CTV, in which viral replication is 
controlled by the PEG-Prom and which also expresses mda-7/IL-24 in Ad.5/3 background, is 
depicted in Fig. 1 and described in details in Materials & Methods. As a control we used Ad.5-
vec (replication-incompetent empty Ad.5), Ad.5/3-vec (replication-incompetent empty Ad.5/3), 
Ad.5-PEG-E1A, in which viral replication is controlled by the PEG-Prom in Ad.5 background, 
and Ad.5/3-PEG-E1A, in which viral replication is controlled by the PEG-Prom in Ad.5/3 
background. We compared MDA-7/IL-24 expression upon infection of Ad.5/3-CTV and Ad.5-
CTV in prostate carcinoma cells that contain low and high CAR on their surface. For this 
purpose, we used PC-3 cells, which have a reduced level of CAR (D value 0.32) in comparison 
with high CAR prostate carcinoma cells DU-145 (D value 0.92) (19). In PC-3 cells MDA-7/IL-
24 expression was significantly higher upon infection with Ad.5/3-CTV, as compared to Ad.5-
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CTV, whereas infection with both Ad.5/3-CTV and Ad.5-CTV in DU-145 cells resulted in the 
expression of similar amount of MDA-7/IL24 (Fig. 2A and 2B). Infection with none of the 
control Ad resulted in MDA-7/IL-24 expression. These findings indicate that infection with 
Ad.5/3-CTV resulted in enhanced transgene delivery in low CAR containing prostate cancer cells 
compared to Ad.5-CTV, and both CTVs are similarly efficient in transgene delivery in high CAR 
prostate cancer cells.  A similar pattern was also observed when Ad replication was analyzed by 
E1A expression in PC3 and DU-145 cells. In DU-145 cells replicating viruses from both Ad.5 
and Ad.5/3 background showed similar replication pattern, while in PC-3 cells replication of 
Ad.5/3 was significantly higher than that of Ad.5 (Fig. 2A and 2B). The efficacy of Ad.5/3-CTV 
and Ad.5-CTV in reducing the cell viability of prostate cancer cells was evaluated by MTT assay. 
Ad.5/3-CTV infection resulted in significantly augmented reduction in the viability of PC-3 cells 
compared to Ad.5-CTV infection at m.o.i. of 500 and 1000VP/ cell on day 3 and day 6 post 
infection (Fig. 2C). In DU-145 cells both Ad.5/3-CTV and Ad.5-CTV showed comparable 
efficiency in reducing viability at similar doses and time points (Fig. 2D). It should be noted that 
Ad.5-PEG-E1A and Ad.5/3.-PEG-E1A was as effective as Ad.5-CTV and Ad.5/3-CTV in 
reducing cell viability in both cell lines indicating that the profound effect of Ad replication in 
inhibiting cell viability might mask the in vitro growth inhibitory effects of mda-7/IL-24. In 
these contexts, in vivo evaluation of CTV is mandatory to confirm the ‘by-stander’ effect exerted 
by mda-7/IL-24. 
Ad.5/3-CTV, but not Ad.5-CTV, induces ER stress and apoptosis, and overcomes the therapy 
resistant PC-3-Bcl-2 tumor cells. We next analyzed the modulation of mda-7/IL-24 downstream 
genes and signals that confer its tumor suppressor properties upon infection with Ad.5/3-CTV 
and Ad.5-CTV in PC-3 cells. Ad.5/3-CTV induces an ER stress response (unfolded protein 
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response) and we therefore checked the expression levels of ER-stress markers. In PC-3 cells, the 
levels of BiP/GRP78 and GRP94 were significantly higher upon infection with Ad.5/3-CTV 
when compared with Ad.5-CTV, Ad.5/3-CTV also efficiently induced apoptosis as evidenced by 
increased cleavage of PARP (Fig. 3A). These findings further confirm that Ad.5/3 chimerism 
maintains the bona fide downstream effects exerted by mda-7/IL-24.  
Bcl-2 gene family plays a central role in PC and over expression of Bcl-2 gene family confers 
resistance to cancer therapeutics (22). In this context, we evaluated the efficacy of Ad.5/3-CTV 
vs Ad.5-CTV in the PC-3-Bcl-2 cells (PC3 cells that stably over express Bcl-2) which are 
resistant to mda-7/IL-24-mediated killing (22). As a control we used PC-3-Neo cells that are 
stably transfected with the empty vector. In MTT assays Ad.5-CTV did not significantly affect 
the cell viability of the PC-3-Bcl-2 cells, although it significantly inhibited the viability of PC-3-
Neo cells (Fig. 3).  However, Ad.5/3-CTV markedly inhibited viability of both PC-3-Neo and 
PC-3-Bcl-2 cells. These findings indicate the potential therapeutic application of Ad.5/3-CTV in 
prostate cancer patients frequently showing Bcl-2 over expression. 
Ad.5/3-CTV eradicates primary and inhibits distant PC-3-Bcl-2 xenografts in nude mice. To 
validate if the in vitro enhanced efficacy of Ad.5/3-CTV compared to Ad.5-CTV is also translated 
to the in vivo situation in low CAR PC cells, subcutaneous PC-3-Bcl-2 tumor xenografts were 
established in the right and left flanks of athymic nude mice. After ~7 to 10 days palpable tumors 
of ~100 mm3 developed and the mice received 9 intratumoral injections only in the left flank 
tumors over a 4-week period with 1 X 1010 viral particles per 100 µL. The Ad used were Ad.5-
vec, Ad.5/3-vec, Ad.5-PEG-E1A, Ad.5/3-PEG-E1A, Ad.5-CTV and Ad.5/3-CTV. No injections 
were administrated to right flank tumors.  PC-3-Bcl-2 cells formed large, aggressive and actively 
proliferating tumors on both flanks in Ad.5-vec, Ad.5/3-vec, Ad.5-PEG-E1A and Ad.5-CTV 
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treated groups. Although Ad.5/3-PEG-E1A inhibited the growth of tumors on the left flank, it 
had no effect on the distant tumor on the right flank (Figure 4). In contrast, Ad.5/3-CTV 
produced a dramatic effect in eradicating the tumor on the left flank and profoundly inhibiting 
tumor growth on the right flank compared to the rest of the groups. These results show definitive 
evidence for enhanced therapeutic efficacy of Ad.5/3-CTV as compared to Ad.5-CTV in prostate 
tumor cells with reduced CAR, and highlight the potent ‘by-stander’ anticancer activity of mda-
7/IL-24 that causes growth inhibition of right-sided non-injected tumors. We detected the 
efficacy of Ad.5/3-CTV and Ad.5-CTV in expressing mda-7/IL-24 in vivo by western blot 
analysis of the total protein extracts from the harvested tumors. Ad.5/3-CTV generated a stronger 
MDA-7/IL-24 protein in both flanks, validating the previously reported “bystander” effect of 
MDA-7/ IL-24 (9, 10, 23), when compared to the weak expression of Ad.5-CTV on the left flank 
and no expression on the right flank (Figure 4E). These findings support that in low CAR 
prostate cancer cells, Ad.5/3-CTV can generate robust expression of MDA-7/IL-24 protein that is 
sufficient for inhibition of cell proliferation and angiogenesis, and exerting the ‘by-stander’ 
activity of MDA-7/IL-24 in the distant tumor. 
Combination treatment of Ad.5/3-CTV and BI-97C1 (Sabutoclax) potentiates inhibition of 
prostate tumor growth in vivo in immune competent animals. Because PC is a relatively slow-
growing disease, repeated systemic gene therapy applications in combination with anti-tumor 
chemotherapeutic agents over the life span of the patient may be appropriate (24). For 
chemotherapeutic agent we used BI-97C1 (Sabutoclax), which is a pure optical derivative of the 
Apogossypol (25). Apogossypol derivatives antagonize the antiapoptotic Bcl-2 family members 
including Bcl-2 and Mcl-1 (26). MDA-7/IL-24 induces cancer-specific apoptosis through the 
translational inhibition of Mcl-1(27). BI-97C1 targeting sensitizes prostate cancer cells to mda-
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7/IL-24-mediated toxicity in vitro (28). Experiments were performed to determine if Ad.5/3-CTV 
in combination with BI-97C1 could inhibit prostate tumor growth in vivo. The used animal 
model in this study is the spontaneous immunocompetent transgenic mouse model of prostate 
cancer (the Hi-Myc mouse), in which the prostate-specific expression of human c-Myc is driven 
by the rat probasin promoter with two androgen response elements (ARR2/probasin promoter). 
Hi-Myc mouse develop prostatic intraepithelial neoplasia (mPIN) as early as 2 to 4 weeks of age 
and invasive adenocarcinoma of the prostate at 6 months (29). We started the treatment at 22 
weeks of age. The ability to deliver Adenoviruses systemically is limited by sequestering of the 
virus in the liver and clearance of the virus by the immune system (30-32). To overcome those 
problems we employed microbubble-targeted ultrasound destruction (UTMD) (33, 34) approach 
in which microbubbles incorporating Adenoviruses are targeted to release the therapeutic virus at 
the tumor site using ultrasound. Using the ultrasound to sonicate the microbubbles creates 
transient nonlethal perforations in cells and other membranes (35). In this context, systemic and 
targeted delivery of mda-7/IL-24 to the prostate of Hi-Myc mouse was performed by tail vein 
injection of microbubble (MB) incorporating Ad.5/3-vec, Ad.5/3-PEG-E1A or Ad.5/3-CTV 
followed by sonoporation in the prostatic area (33). A total of 8 tail vein injections of each group 
were administered over a 4-week period. BI-97C1 was administered intraperitoneally (i.p.) in 
each group at 3mg/kg thrice a week throughout the study. The prostates of Hi-myc mice were 
sectioned and stained for MDA-7/IL-24 and Ki-67, proliferation marker, and apoptosis induction 
was analyzed by TUNEL assay. MDA-7/IL-24 expression was accompanied by increased 
TUNEL positive cells and decreased Ki-67 positive cells in the Ad.5/3-CTV and BI-97C1 treated 
group compared to the control groups (Figure 5). Although Ad.5/3-CTV alone induced 
significant apoptosis it was markedly augmented in combination with BI-97C1. 
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Discussion  
Since prostate cancer is commonly a relatively slow-growing disease, it may be necessary to use 
repeated gene therapy approaches, with single or multiple genes, over the lifespan of the patient 
(36). In these contexts, the use of conditionally replicating adenoviruses to administer therapeutic 
gene or gene products in prostate tumor cells represents a viable treatment option (37, 38). A 
major challenge for effective gene therapy using conditionally replicating Ads is the ability to 
specifically deliver nucleic acids directly into diseased tissue. Progress in gene therapy has been 
hampered by concerns over the safety and practicality of viral vectors, particularly for 
intravenous delivery, and the inefficiency of currently available non-viral transfection techniques 
(36). Recombinant Ads are one of the most common gene transfer vectors utilized in human 
clinical trials, but systemic administration of this virus is thwarted by host innate and adaptive 
antiviral immune responses which can limit and/or preclude repetitive treatment regiments (39).  
The advantage and superiority of our gene therapy approach is because the used therapeutic gene 
is a novel IL-10-family member cytokine; mda-7/IL-24. Early phase clinical studies suggest that 
mda-7/IL-24 may be an ideal agent for gene therapy of primary and metastatic melanoma (6). It 
is capable of selectively targeting cancer cells in vitro and in vivo for apoptosis or toxic 
autophagy, whereas in diverse normal cells it does not show cell toxicity (5-8, 40, 41). 
Additionally, the secreted MDA-7/IL-24 exhibits a potent “bystander” anti-tumor effect on 
cancer (9, 10, 23, 42).  
The infectivity of Adenoviruses and their limitation of infecting low CAR on different prostate 
cancer cells have been previously analyzed (43, 44). DU-145 has high CAR, while PC-3 has 
lower cell surface CAR, which makes it relatively resistant to adenovirus infection. To overcome 
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the viral resistance of PC-3, it has been genetically engineered to increase 35% of CAR-positive 
cells to 86% CAR-positive cells (44). Consequently, infection with a recombinant Ad.5 CMV-
p21virus showed relatively higher levels of p21 protein in virus-infected cells resulting in 
apoptosis (44). These studies highlight the importance of relative levels of CAR as a major 
determinant of Ad-based gene therapy approaches. Further, in our study, we constructed a 
bipartite Ad where the selective tumor cytotoxic gene mda-7/IL-24 driven by a CMV promoter 
and E1A  is driven by a minimal active region of the promoter of progression elevated gene-3 
(PEG-3), that restricts viral replication to cancer cells with limited activity in normal cells (18, 
45). Consequently, the PEG-Promoter may provide a generic tool for ensuring cancer selectivity. 
Ad.5/3-CTV contains a chimeric fiber with the knob domain of human Ad.3 in the Ad.5 capsid 
(Ad.5/3), which allows viral infectivity regardless of the CAR expression status of tumor cells 
thus permitting efficient viral infectivity of low and high CAR expressing tumor cells (46, 47) , 
The finding that Ad.5/3-CTV eradicated not only primary injected tumors, but also distant non-
injected tumors derived from a resistant prostate cancer cell line in a nude mouse xenograft 
model support the anticancer potency of this cancer therapeutic virus. The Ad.5/3-CTV is 
capable of infecting cancer cells regardless of their cell surface CAR status, which makes it more 
useful and efficient than Ad.5-CTV that fails to efficiently deliver the therapeutic gene in low 
CAR receptor prostate cancer cells. 
Systematic delivery of adenoviruses is challenged by sequestering of adenoviruses in the liver 
limiting virus delivery to disseminated tumors (32) and neutralization of viruses by the immune 
system (32). To prevent trapping of CTV in the liver and elimination of viruses by the immune 
system of the Hi-Myc PC transgenic mouse we have developed a novel approach in which 
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tropism modified CTV is incorporated in a perfluorocarbon microbubble that is administered 
systemically to be released in the prostate area through ultrasound, a UTMD approach (33).  
In summery gene therapy for prostate cancer is a promising field; the prostate gland is not vital 
for survival and is accessible by ultrasound; Ad.5/3-CTV can be either injected directly into the 
primary tumor or delivered through UTMD of the microbubbles incorporated viruses and 
therefore express MDA-7/IL-24; the replication of this virus and the expression of the 
therapeutic genes can be specified in cancer cells but not normal cells through its cancer-specific 
and tissue-specific PEG promoter; and disease progression can be monitored by measuring 
prostate-specific antigen (PSA) (48, 49). In these contexts, the use of Ad.5/3-CTV to administer 
the therapeutic and cytotoxic mda-7/IL24 selectively induce cytolysis in prostate tumor cells 
represent viable treatment options (38, 50).  
 
Materials and Methods  
Cell lines, culture conditions, and viability assays.  DU-145 and PC-3 prostate cancer cells were 
obtained from the American Type Culture Collection and cultured as described (22).   The Cell 
viability was determined by standard 3-(4, 5-dimethylthiazol-2-yl)-2,5- diphenyltetrazolium 
bromide (MTT) assays (22).  
Construction of Ad.5/3-CTV.  The genome of Ad5/3.PEG-E1.mda-7 was generated in three 
consecutive steps (Fig. 1). 1) Homologous recombination of pAd5/3 genomic plasmid with 
pShuttlE3 plasmid containing the mda-7/IL-24 expression cassette and kanamycin selection 
results in pAd5/3.E3-mda-7 genome. 2) pAd5/3.E3-mda-7 is cut with Swa I to excise the 
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kanamycin resistance gene. 3) The resultant pAd5/3.E3-mda-7 plasmid is recombined with 
pShuttlE1 plasmid containing E1A-1B genes under control of PEG3 promoter resulting in 
Ad5/3.PEG-E1.mda-7 genomic plasmid. This plasmid is digested with Pac I to release viral ITRs 
and transfected in A549 cells to rescue the CRCA Ad.5/3-CTV.  
Preparation of whole-cell lysates and Western blot analyses. Preparation of whole-cell lysates 
and Western blot analyses were performed as previously described (18, 33). The primary 
antibodies used were anti-MDA-7/IL-24 (1:1,000; mouse monoclonal; Gen Hunter  Corporation 
), anti-EF1α (1:1,000; mouse monoclonal;  Millipore), anti-Mcl-1 (1:500; mouse monoclonal; 
santa cruz), anti-BiP/Grp78  (1:500; rabbit monoclonal; santa cruz), anti-GRP94 (1:1000; rabbit 
monoclonal; sigma), anti-PARP (1:1000; rabbit monoclonal; cell signalling). 	  	  
 Human prostate cancer xenografts in athymic nude mice. PC-3-Bcl-2 cells (2× 106) were 
injected s.c. in 100 µL of 1:1 PBS and DBmatrigel in left and right flanks of male athymic nude 
mice (NCRnu/nu , 6-8 weeks old, ~20 g body weight) (18, 19). After establishment of visible 
tumors of ~100-mm3, requiring ~7-10 days, intratumoral injections of different adenoviruses 
were given only to the tumors on the left flank at a dose of 1× 1010 viral particles in 100 µl. The 
injections were given twice a week for four weeks. A minimum of five animals was used per 
experimental point. Tumor volume was calculated using the formula: π/6 × larger diameter × 
(smaller diameter) 2. At the end of the experiment, the animals were sacrificed, and the tumors 
were removed and weighed.  
Hi-Myc mice and animal husbandry protocol. The VCU Institutional Animal Care and Use 
Committee approved the experimental protocol used in this study and the animals were cared for 
in accordance with institutional guidelines. Hi-Myc transgenic mice, in which the prostate-
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specific expression of human c-Myc is driven by the rat probasin promoter with two androgen 
response elements (ARR2/probasin promoter) were used in this study (29). Mice were obtained 
from the Mouse Repository of the National Cancer Institute Mouse Models of Human Cancer 
Consortium at NCI Frederick, MD, USA. Mouse-tail DNA was isolated using the DNeasy Blood 
& Tissue Kit from QIAGEN (Valencia, CA) and subjected to a PCR-based screening assay for 
genotyping. For genotyping Hi-MYC mice, the upstream primer (located within the ARR2-PB 
promoter), 5’-AAACATGATGACTACCAAGCTTGGC-3’ and the downstream primer (within 
the MYC cDNA sequence) 5’-ATGATAGCATCTTGTTCTTAGTCTTTTTCTTAATAGGG-3’ 
were used to generate a PCR product of 177 base pairs.  
Preparation of microbubbles (MBs), ultrasound (US) platform, ultrasound-targeted 
microbubble destruction (UTMD) and BI-97C1. Preparation of MBs followed by UTMD for 
delivery of mda-7/IL-24 expressing Ads has been described previously (33). Targeson 
(Targeson) custom synthesis US contrast agent (perfluorocarbon MBs, encapsulated by a lipid 
monolayer and poly(ethyleneglycol) stabilizer) were obtained. MBs were reconstituted in the 
presence or absence of 1 ml of 1 × 1011 viral particles of indicated Ads and unenclosed surface-
associated Ads were treated with complement as previously described (34). For in vivo 
experiments US exposure was achieved with a Micro-Maxx SonoSite (SonoSite) US machine 
equipped with the transducer L25 set at 0.7 Mechanical Index, 1.8 MPa for 10 minutes. Mice 
were sedated in an IMPAQ6 anesthesia apparatus (VetEquip, Pleasanton, CA) that was saturated 
with 3–5% isofluorane and 10–15% oxygen with the aid of a precision vaporizer to deliver the 
appropriate amount of anesthetic and to induce anesthesia. For microbubble/Adenovirus 
injection a 27-gauge needle with a heparin lock was placed within a lateral tail vein for 
administration of contrast material. The mice received injections of 100 µl of MBs with Ads 
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through the tail vein 8 times in the span of 4 weeks. Ultrasound (sonoporation) was performed 
with a SonoSite scanner (SonoSite) equipped with the transducer L25 set at 0.7 Mechanical 
Index, 1.8 MPa for 10 min in the ventral side of mice in the prostatic area. BI-97C1 was 
administered intraperitoneally at a dose level of 3 mg/kg thrice a week for the duration of the 
study (total 12 injections). Compounds dissolved in 500 µL of solvent (ethanol/Cremophor 
EL/saline = 10:10:80) were injected intraperitoneally. At the end of the experiment, the Hi-Myc 
mice were sacrificed and the prostate was dissected. The harvested prostate was preserved in 
neutral buffered formalin at 4°C before embedding in paraffin for immunohistochemical 
analysis. 
Immunohistochemical staining. For immunohistochemical (IHC) analysis, formalin-fixed and 
paraffin-embedded specimens were sectioned 3–4-µm thick. Sections were deparaffinized, re-
hydrated and then quenched in 3% H2O2 for 20 min. Sections were washed with PBS and 
blocked in PBS containing 1% BSA for 20 min at 37°C. Monoclonal anti-MDA-7/IL-24 (1:200) 
was incubated for 3 hr at room temperature and then washed 3X in PBS. Sections were incubated 
with an avidin-biotin-peroxidase complex (Vectastain Elite ABC kit, Vector Laboratories) and 
then washed 2X in PBS. The immunoreactivity was determined using diaminobenzidine (DAB) 
as the final chromogen. Finally, sections were counterstained with Meyer’s Hematoxylin, 
dehydrated through a sequence of increasing concentration of alcohol, cleared in xylene and 
mounted with epoxydic medium. Sections were also processed for hematoxylin and eosin (H&E) 
staining.  
Determination of apoptotic cells by TUNEL assay. For TUNEL assays, we used the DeadEnd 
Colorimetric TUNEL Assay kit (Promega, Madison, WI) performed according to the 
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manufacturer’s instructions. Briefly, paraffin-embedded slides were deparaffinized and 
rehydrated. Pre-equilibrated slides were labeled with a labeling DNA-strand break solution 
containing a biotinylated nucleotide mix (60 min at 37°C). After several washes in 2X SSC and 
PBS, slides were blocked with hydrogen peroxide (3–5 min at room temperature). After several 
washes in PBS, the slides were mounted with mounting solution with DAPI. Apoptotic cells on 
the slides were observed under an Olympus epifluorescence microscope (X10 magnification; 
Olympus, Center Valley, PA) in randomly chosen fields. For detection of apoptosis in a time-
dependent manner in vitro, PC3 cells were grown in microscopic slide culture chambers (BD 
Bioscience) and cells were treated with Ad.5/3-mda-7 and BI-97C1 after which the cells were 
fixed with 4% formaldehyde at the indicated time and TUNEL assays were performed as per the 
manufacturer’s instruction using an Olympus epifluorescence microscope (X10 magnification; 
Olympus, Center Valley, PA) 
Statistical analysis. Statistical analysis was done using student ttest. P < 0.05 was considered 
significant. 
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Figure Legends:  
 
Figure 1. Generation of tropism-modified cancer terminator virus (Ad.5/3-CTV). Schematic 
representation showing the construction of tropism modified cancer terminator virus for delivery 
of mda-7/IL-24. The detailed procedure has been described in material and methods.  
 
Figure 2. Ad.5/3-CTV enhanced mda-7/IL-24 expression and inhibition of cell viability in 
low CAR prostate cancer cells. a) DU-145 and PC-3 cells were infected with the indicated 
vp/cell of Ad.5-vec, Ad.5-PEG-E1A, Ad.5-CTV, Ad.5/3-vec, Ad.5/3-PEG-E1A, and Ad.5/3-CTV 
for 48 hr and total proteins were isolated. The expression of MDA-7/IL-24, E1A and EF-1α (as a 
loading control) proteins were analyzed by Western blot analyses. b) Cell viability using the 
MTT assay was quantified after 3 days and 6 days with the indicated doses of vp/cell of Ad.5-
CTV, Ad.5/3-CTV and their respective controls. Results are the mean ± S.D (n=3). 
 
Figure 3. Ad.5/3-CTV, but not Ad.5-CTV, induces ER stress and apoptosis, and overcomes 
the therapy resistant PC-3-Bcl-2 tumor cells. a) Changes in BiP/GRP78, GRP94 and 
activation of PARP were detected by Western blot analysis after 2 days of treating PC-3 cells 
with the indicated Adenoviruses. b+c) Cell viability using the MTT assay was quantified after 3 
days and 6 days with the indicated doses of vp/cell of Ad.5-CTV, Ad.5/3-CTV and their 
respective controls. Results are the mean ± S.D (n=3). 
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Figure 4. Ad.5/3-CTV eradicates primary and inhibits distant PC-3-Bcl-2 xenografts in 
nude mice. Tumor xenografts from PC-3-Bcl-2 cells were established in athymic nude mice in 
both right and left flanks; and only tumors on the left side were injected with the indicated 
adenoviruses over a 4 week period (total of nine injections). Measurements of PC-3 xenograft 
tumor volumes of a) left and b) right flanks; points, average (with a minimum of five mice in 
each group); bars, + S.D. Inset contains a photograph of the animals of each representative 
group. c) Photograph of the PC-3-Bcl-2 xenograft tumor at the end of the study. D) Measurement 
of tumor weight at the end of the study; columns, mean (with at least five mice in each group); 
bars, + S.D.  E) Western blot analysis of protein extracts from representative PC-3-Bcl-2 tumor 
samples treated Ad.5-vec, Ad.5/3-vec, Ad.5-PEG-E1A, Ad.5/3-PEG-E1A , Ad.5-CTV,  Ad.5/3-
CTV. The immunoblot was reacted with anti-MDA-7/IL-24.  
 
 Figure 5: Combination treatment of Ad.5/3-CTV and BI-97C1 potentiates inhibition of 
prostate tumor growth in vivo in immune competent animals.  Hi-Myc mice were treated as 
described in panel C and at the end of the experiment the mice were sacrificed and the prostates 
were collected. The paraffin-embedded sections obtained from the prostate and 
immunohistochemistry was performed to measure systemic transgene delivery by staining with 
anti-MDA-7/IL-24. Apoptosis in the prostate section was detected by TUNEL assay. Nuclei 
were visualized with DAPI. Wild type mice served as a control for these experiments.	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